<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102424</article-id><article-id pub-id-type="doi">10.7554/eLife.102424</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102424.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Elevated pyramidal cell firing orchestrates arteriolar vasoconstriction through COX-2-derived prostaglandin E2 signaling</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Le Gac</surname><given-names>Benjamin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4703-6217</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tournissac</surname><given-names>Marine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1990-5075</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Belzic</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Picaud</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dusart</surname><given-names>Isabelle</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3211-4323</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Soula</surname><given-names>Hédi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5306-9712</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dongdong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6731-4771</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Charpak</surname><given-names>Serge</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5516-1245</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cauli</surname><given-names>Bruno</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1471-4621</contrib-id><email>bruno.cauli@upmc.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne Université, CNRS, Inserm, Neuro-SU</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01c2cjg59</institution-id><institution>Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris-Seine</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000zhpw23</institution-id><institution>Sorbonne Université, CNRS, Inserm, Institut de la Vision, F-75012</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00qdphm77</institution-id><institution>Sorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches, NutriOmics, Research Unit</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Uhlirova</surname><given-names>Hana</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03613d656</institution-id><institution>Faculty of Mechanical Engineering, Brno University of Technology and Institute of Physical Engineering</institution></institution-wrap><country>Czech Republic</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Huguenard</surname><given-names>John R</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>04</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP102424</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-10-10"><day>10</day><month>10</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-08-13"><day>13</day><month>08</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.27.586974"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-13"><day>13</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102424.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-03-06"><day>06</day><month>03</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102424.2"/></event></pub-history><permissions><copyright-statement>© 2024, Le Gac et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Le Gac et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102424-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102424-figures-v1.pdf"/><abstract><p>Neurovascular coupling, linking neuronal activity to cerebral blood flow, is essential for brain function and underpins functional brain imaging. Whereas mechanisms involved in vasodilation are well-documented, those controlling vasoconstriction remain overlooked. This study unravels the mechanisms by which pyramidal cells elicit arteriole vasoconstriction. Using patch-clamp recording, vascular and Ca<sup>2+</sup> imaging in mouse cortical slices, we show that strong optogenetic activation of layer II/III pyramidal cells induces vasoconstriction, correlating with firing frequency and somatic Ca<sup>2+</sup> increase. Ex vivo and in vivo pharmacological investigations indicate that this vasoconstriction predominantly recruits prostaglandin E2 through the cyclooxygenase-2 pathway, and activation of EP1 and EP3 receptors. We also present evidence that specific interneurons releasing neuropeptide Y, and astrocytes, through 20-hydroxyeicosatetraenoic acid, contribute to this process. By revealing the mechanisms by which pyramidal cells lead to vasoconstriction, our findings shed light on the complex regulation of neurovascular coupling.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>neurovascular coupling</kwd><kwd>pyramidal cells</kwd><kwd>prostaglandin E2 signaling</kwd><kwd>optogenetics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021790</institution-id><institution>Fondation pour la Recherche sur Alzheimer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Le Gac</surname><given-names>Benjamin</given-names></name><name><surname>Belzic</surname><given-names>Esther</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-17-CE37-0010-03</award-id><principal-award-recipient><name><surname>Cauli</surname><given-names>Bruno</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>CE37_2020_TF-fUS-CADASIL</award-id><principal-award-recipient><name><surname>Charpak</surname><given-names>Serge</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-20-CE14-0025</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Dongdong</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-23-CE14-0038-01</award-id><principal-award-recipient><name><surname>Cauli</surname><given-names>Bruno</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100014439</institution-id><institution>FONDATION ALZHEIMER</institution></institution-wrap></funding-source><award-id>M21JRCN009</award-id><principal-award-recipient><name><surname>Charpak</surname><given-names>Serge</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>i-Bio Initiative</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cauli</surname><given-names>Bruno</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><award-id>SPF201909009103</award-id><principal-award-recipient><name><surname>Tournissac</surname><given-names>Marine</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Increased neuronal activity of cortical pyramidal cells can paradoxically reduce cerebral blood flow via vasoconstriction mediated by glutamate and lipid messengers.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The brain critically depends on the uninterrupted blood supply provided by a dense vasculature (<xref ref-type="bibr" rid="bib77">Schmid et al., 2019</xref>). Cerebral blood flow (CBF) is locally and temporally controlled by neuronal activity, by an essential process called neurovascular coupling (NVC), and is impaired in early stages of numerous neurological disorders (<xref ref-type="bibr" rid="bib37">Iadecola, 2017</xref>). NVC also serves as the physiological basis for functional brain imaging widely used to map neuronal activity. Neuronal activity increases CBF within seconds (<xref ref-type="bibr" rid="bib37">Iadecola, 2017</xref>). In the cerebral cortex, the hyperemic response linked to neural activity is supported by dynamically controlled vasodilation that is spatially and temporally constrained by vasoconstriction in a second phase (<xref ref-type="bibr" rid="bib22">Devor et al., 2007</xref>). Conversely, vasoconstriction and decreased CBF usually correlate with reduced neuronal activity (<xref ref-type="bibr" rid="bib22">Devor et al., 2007</xref>; <xref ref-type="bibr" rid="bib80">Shmuel et al., 2002</xref>).</p><p>Mounting evidence indicates that the positive correlation between neuronal activity and CBF is not always maintained under physiological conditions: (i) robust sensory-evoked vasodilation can occur in the absence of substantial neuronal response (<xref ref-type="bibr" rid="bib57">O’Herron et al., 2016</xref>), (ii) conversely, pronounced neuronal activity is not systematically associated with increased hemodynamics (<xref ref-type="bibr" rid="bib50">Ma et al., 2016</xref>), (iii) CBF is decreased in several cortical areas despite local increase in neuronal activity (<xref ref-type="bibr" rid="bib23">Devor et al., 2008</xref>), and (iv) optogenetic simulation of inhibitory GABAergic interneurons results in vasodilation (<xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). Furthermore, in pathological conditions with intense neuronal activity such as epileptic seizures, a sustained hypoperfusion induced by vasoconstriction is observed (<xref ref-type="bibr" rid="bib25">Farrell et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Tran et al., 2020</xref>).</p><p>NVC is achieved by the synthesis and release of vasoactive messengers within the neurovascular unit (<xref ref-type="bibr" rid="bib37">Iadecola, 2017</xref>), which act on the contractility of mural cells (smooth muscle cells and pericytes) to control vessel caliber and CBF along the vascular tree (<xref ref-type="bibr" rid="bib70">Rungta et al., 2018</xref>). Pial and penetrating arterioles, which have a higher density of contractile mural cells and control their diameter faster than capillaries (<xref ref-type="bibr" rid="bib34">Hartmann et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Hill et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Rungta et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Rungta et al., 2018</xref>), play a key role in regulating CBF.</p><p>Different experimental approaches, each with their advantages and limitations, have allowed the identification of several mediators of NVC (<xref ref-type="bibr" rid="bib33">Grutzendler and Nedergaard, 2019</xref>; <xref ref-type="bibr" rid="bib36">Iadecola and Nedergaard, 2007</xref>). Ex vivo brain slices provide a well-controlled environment, ideal for pharmacological investigations to dissect the underlying mechanisms. However, they lack connectivity and blood flow which provides both vascular tone and natural oxygenation and therefore require in vivo validation. Conversely, pharmacological studies are more challenging with in vivo preparations. Awake animals allow physiologically relevant context with largely undisturbed network and neuromodulatory activity. However, this preparation is subject to brain state changes which may affect network activity, metabolism, and vascular physiology (<xref ref-type="bibr" rid="bib33">Grutzendler and Nedergaard, 2019</xref>), potentially complexifying the analysis of specific mechanisms of NVC. Although chronic anesthetized animals have reduced network and neuromodulation activity, the NVC response is only slowed (<xref ref-type="bibr" rid="bib71">Rungta et al., 2021</xref>), providing a valuable model for validating ex vivo observations.</p><p>Messengers of vasodilation released by excitatory neurons, GABAergic interneurons, astrocytes, or endothelial cells, include nitric oxide, K<sup>+</sup>, arachidonic acid derivatives such as prostaglandin E2 (PGE2; <xref ref-type="bibr" rid="bib37">Iadecola, 2017</xref>), or more recently glutamate (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>). Despite its physio pathological importance, vasoconstriction is less understood with fewer cell types and vasoactive messengers that have been identified. It is now generally accepted that GABAergic interneurons are key players in vasoconstriction by releasing neuropeptide Y (NPY; <xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). Under certain conditions, astrocytes can also induce vasoconstriction via 20-hydroxyeicosatetraenoic acid (20-HETE) (<xref ref-type="bibr" rid="bib55">Mulligan and MacVicar, 2004</xref>) or high K<sup>+</sup> concentration (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>). However, the involvement of pyramidal cells in vasoconstriction has been overlooked.</p><p>PGE2 has emerged as a bimodal messenger of NVC, similar to K<sup>+</sup> (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>) and glutamate (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>), that can induce either vasodilation (<xref ref-type="bibr" rid="bib30">Gordon et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Lecrux et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Mishra et al., 2016</xref>) or vasoconstriction (<xref ref-type="bibr" rid="bib19">Dabertrand et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rosehart et al., 2021</xref>) depending on its concentration and/or site of action along the vascular tree. Under physiological conditions, PGE2 is produced during NVC by either astrocytes (<xref ref-type="bibr" rid="bib53">Mishra et al., 2016</xref>) or pyramidal cells (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>) via the rate-limiting synthesizing enzymes cyclooxygenase-1 (COX-1) or –2 (COX-2), respectively. Since COX-2-expressing pyramidal cells can release glutamate and PGE2, both of which induce vasoconstriction at high concentrations (<xref ref-type="bibr" rid="bib19">Dabertrand et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rosehart et al., 2021</xref>; <xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>), pyramidal cells may be responsible for vasoconstriction when their spiking activity is high.</p><p>To test this hypothesis, we used ex vivo and in vivo approaches in combination with optogenetics to precisely control pyramidal cell firing in the mouse barrel cortex while monitoring the resulting arteriolar response. We found that pyramidal cells induce vasoconstriction at high stimulation frequency and about half of them express all the transcripts required for a cell autonomous synthesis of the vasoconstrictor messengers PGE2 and prostaglandin F2α (PGF2α). Pharmacological investigations revealed that this neurogenic vasoconstriction depends on COX-2-derived PGE2 via the direct activation of vascular EP1 and EP3 receptors. It also involves the recruitment of intermediary NPY interneurons acting on the Y1 receptor, and, to a lesser extent astrocytes, via 20-HETE and COX-1-derived PGE2. Thus, our study reveals the mechanisms by which high-frequency pyramidal cell firing leads to vasoconstriction.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Pyramidal cells induce vasoconstriction at high firing frequency</title><p>To determine if pyramidal cells action potential (AP) firing can induce vasoconstriction in a frequency-dependent manner, we used optogenetics to induce AP firing while monitoring the resulting vascular response in cortical slices. We used Emx1-cre;Ai32 transgenic mice expressing the H134R variant of channelrhodopsin-2 (ChR2) in the cortical glutamatergic neurons (<xref ref-type="bibr" rid="bib31">Gorski et al., 2002</xref>), conferring robust pyramidal cell photoexcitability (<xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>). Wide-field photostimulation of cortical slices was achieved in layers I to III (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) using 10 s trains of 5ms light pulses (see Materials and methods) delivered at five different frequencies (1, 2, 5, 10 and 20 Hz, <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The occurrence and strength of vasoconstriction depends on the photostimulation frequency of pyramidal cells.</title><p>(<bold>A</bold>) Representative examples of the voltage responses of a layer II-III pyramidal cell (upper traces light grey to black traces) induced by photostimulations (470 nm, 10 s train, 5ms pulses) delivered at 1, 2, 5, 10, and 20 Hz (cyan lower traces) and mean spike success rate (middle trace, n=4 cells from 3 mice). The SEMs envelope the mean traces. The red dashed lines represent a spike success rate of 100%. (<bold>B</bold>) Representative example showing IR-DGC pictures of a layer I penetrating arteriole (1) before a 20 Hz photostimulation, (2) at the maximal diameter decrease, and (3) after 10 min of recording. Pial surface is upward. Yellow calipers represent the measured diameters. White dashed lines indicate the initial position of the vessel wall. Scale bar: 25 µm. (<bold>C</bold>) Kinetics of arteriolar diameter changes induced by photostimulation (vertical cyan bars) at 1 Hz (n=4 arterioles from 3 mice), 2 Hz (n=10 arterioles from 8 mice), 5 Hz (n=6 arterioles from 6 mice), 10 Hz (n=5 arterioles from 5 mice), and 20 Hz (n=10 arteriole from 9 mice). The SEMs envelope the mean traces. The blue trace represents the kinetics of the diameter changes of the arteriole shown in (<bold>B</bold>). (<bold>D</bold>) Effects of the different photostimulation frequencies on AUC of vascular responses during 10 min of recording. Data are presented as the individual values and mean ± SEM. * statistically different from 20 Hz stimulation with p&lt;0.05.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Detection of spikes per light pulse interval from different cells used to determine spike success rate in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig1-data1-v1.xls"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig1-data2-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Vasoconstriction induced by widefield photostimulation is specific of ChR2 expression in pyramidal cells.</title><p>(<bold>A</bold>) Visualization of EYFP-ChR2 fusion transgene fluorescence in a cortical slice of an Emx1-cre;Ai32 mouse at 4 X objective. Note the presence of barrels in layer IV. (<bold>B</bold>) Photobleaching in superficial cortical layers was achieved by widefield illumination at maximum LED power for 1 min with a 40 X objective. The round photobleached area was approximately 0.15 mm². (<bold>C</bold>) Kinetics of vascular responses induced by photostimulation at 20 Hz in cortical brain slices from naive C57bl/6 J (light gray, n=3 arterioles) or ChR2-expressing Emx1-cre;Ai32 mice (black, n=10 arterioles). Dashed line represents the baseline. The SEMs envelope the mean traces. (<bold>D</bold>) Effect of pyramidal cell ChR2 expression on AUC of vascular responses evoked by photostimulation at 20 Hz. The data are shown as the individual values and mean ± SEM. * statistically different with p&lt;0.05.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Vasoconstrictions occurred during the 30 first minutes after pyramidal cells photoactivation.</title><p>(<bold>A</bold>) Kinetics of arteriolar diameter changes induced by photostimulation (vertical cyan bars) at 1 Hz (n=4 arterioles from 3 mice), 2 Hz (n=10 arterioles from 8 mice), 5 Hz (n=6 arterioles from 6 mice), 10 Hz (n=5 arterioles from 5 mice) and 20 Hz (n=10 arterioles from 9 mice) during 30 min recording. The SEMs envelope the mean traces. The blue trace represents the kinetics of the diameter changes of the arteriole shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. (<bold>B, C</bold>) Effects of the different photostimulation frequencies on (<bold>B</bold>) AUC and (<bold>C</bold>) time to peak of vascular responses during the 30 min of recording. Data are presented as the individual values and mean ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig1-figsupp2-v1.tif"/></fig></fig-group><p>First, we ensured the efficiency of the photostimulation paradigm by recording layer II-III pyramidal cells in whole-cell current clamp mode (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We observed that optogenetic stimulation resulted in the firing of an initial AP that was followed by a train of spikes whose amplitude and frequency transiently decreased before reaching a steady state (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, upper traces). Consistent with the kinetic properties of the H134R ChR2 variant (<xref ref-type="bibr" rid="bib48">Lin et al., 2009</xref>) and the intrinsic firing properties of pyramidal cells (<xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref>), the steady-state firing frequency matched the photostimulation frequency up to 5 Hz but was lower at higher frequencies (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, steady-state spike success rate: 100 ± 0% at 1, 2, and 5 Hz, 70 ± 11% at 10 Hz and 55 ± 12% at 20 Hz). These observations demonstrate efficient pyramidal cell activation over a wide range of photostimulation frequencies.</p><p>To test the hypothesis that neuronal activity induces vasoconstriction, we analyzed the optogenetically induced response of penetrating arterioles. Layer I arterioles were imaged for 30 min in cortical slices (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>; <xref ref-type="table" rid="table1">Table 1</xref>) without preconstriction to facilitate observation of vasoconstriction (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>). Examination of the evoked vascular response over 30 min (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) showed that increasing the frequency of photostimulation shifted the overall vascular response from a barely discernible delayed response between 1 Hz and 5 Hz to a sustained vasoconstriction at 10 Hz and above which began less than 2 min after photostimulation (10 Hz: 1.4±0.4 min; 20 Hz: 1.6±0.5 min). Most vessels (n=8 of 10 arterioles) showed a strong and rapid vasoconstriction at 20 Hz. On average, this response peaked at 6.8±2.4 min, much earlier than at lower frequencies, which typically required more than 10 min to reach a maximum (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>, 1 Hz: 15.6±4.0 min; 2 Hz: 13.2±2.3 min; 5 Hz: 16.0±3.6 min; 10 Hz: 15.7±2.4 min). Because the vascular response shifted to reliable vasoconstriction, with onset and peak in less than 2 and 10 min, respectively, similar to previous observations in cortical slices (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>), when the frequency of photostimulation was increased to 20 Hz, we defined the first 10 min of recording as the vasoconstriction time frame for subsequent comparisons and analyses. While photostimulation at 1–5 Hz failed to elicit fast reliable vascular responses (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>), 10 Hz photostimulation predominantly induced vasoconstriction (n=4 of 5 arterioles, <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>, area under the curve (AUC)=–1.7 ± 1.1 x 10<sup>3</sup> %.s, n=5). This response was even more pronounced at 20 Hz, as all arterioles showed vasoconstriction of high magnitude (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>; AUC = –3.7 ± 0.7 x 10<sup>3</sup> %.s, F<sub>(4, 30)</sub>=6.135, p=9.89 x 10<sup>–4</sup>, one-way ANOVA, n=10 arterioles). This difference was particularly striking when comparing the magnitude at 20 Hz (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) with those at 1 Hz (t<sub>(12)</sub> = –3.48, p=0.0407, t-test), 2 Hz (t<sub>(18)</sub> = –4.09, p=0.0250, t-test) and 5 Hz (t<sub>(14)</sub> = –3.7, p=0.0346, t-test). Intense optogenetic stimulation of pyramidal cells has been shown to elicit cortical spreading depression (<xref ref-type="bibr" rid="bib17">Chung et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Pham et al., 2024</xref>), which induces vasoconstriction (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>) and fast cell swelling (<xref ref-type="bibr" rid="bib104">Zhou et al., 2010</xref>). We ruled out this possibility by showing that the rate of change in light transmittance associated with cell swelling remained below that of cortical spreading depression (<xref ref-type="bibr" rid="bib104">Zhou et al., 2010</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). On the other hand, ChR2-independent vascular changes induced by high light intensity have been reported (<xref ref-type="bibr" rid="bib69">Rungta et al., 2017</xref>). We verified that 20 Hz photostimulation did not induce a vascular response in wild-type mice that do not express ChR2 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Taken together, our observations indicate that photostimulation of pyramidal cells produces a frequency-dependent vasoconstriction.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Morphological and physiological properties, and neurovascular responses of diving arterioles used in the analysis of the frequency-dependence of the polarity of neurovascular response evoked by pyramidal cells.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Properties of individual arterioles used for <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Frequency</th><th align="left" valign="bottom">1 Hz</th><th align="left" valign="bottom">2 Hz</th><th align="left" valign="bottom">5 Hz</th><th align="left" valign="bottom">10 Hz</th><th align="left" valign="bottom">20 Hz</th></tr></thead><tbody><tr><td align="left" valign="bottom">Number of arterioles</td><td align="left" valign="bottom">n=4</td><td align="left" valign="bottom">n=10</td><td align="left" valign="bottom">n=6</td><td align="left" valign="bottom">n=5</td><td align="left" valign="bottom">n=10</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>Resting stability (%</bold>)</td><td align="char" char="plusmn" valign="bottom">1.2±0.2</td><td align="left" valign="bottom">1.6±0.2</td><td align="left" valign="bottom">1.6±0.2</td><td align="left" valign="bottom">1.3±0.2</td><td align="left" valign="bottom">1.0±0.1</td></tr><tr><td align="left" valign="bottom" colspan="5">F (4, 30)=2.161<break/>p=0.098</td></tr><tr><td align="left" valign="bottom" colspan="5">n.s.</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>Wall thickness (µm</bold>)</td><td align="char" char="plusmn" valign="bottom">3.6±0.8</td><td align="left" valign="bottom">3.8±0.3</td><td align="left" valign="bottom">3.2±0.5</td><td align="left" valign="bottom">4.1±0.8</td><td align="left" valign="bottom">4.0±0.2</td></tr><tr><td align="left" valign="bottom" colspan="5">F (4, 30)=0.656<break/>p=0.627</td></tr><tr><td align="left" valign="bottom" colspan="5">n.s.</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>Area under the curve after photostimulation (AUC; x10<sup>3</sup> %.s</bold>)</td><td align="char" char="plusmn" valign="bottom">0.5±0.2</td><td align="left" valign="bottom">0.0±0.5</td><td align="left" valign="bottom">0.2±1</td><td align="left" valign="bottom">–1.7±1.1</td><td align="left" valign="bottom">–3.7±0.7</td></tr><tr><td align="left" valign="bottom" colspan="5">F (4, 30)=6.135<break/>p=0.00099</td></tr><tr><td align="char" char="." valign="bottom" colspan="5">***</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>Maximal dΔT/dt (%.s<sup>–1</sup></bold>)</td><td align="char" char="plusmn" valign="bottom">0.19±0.09</td><td align="left" valign="bottom">0.64±0.14</td><td align="left" valign="bottom">0.22±0.04</td><td align="left" valign="bottom">0.43±0.19</td><td align="left" valign="bottom">0.8±0.11</td></tr><tr><td align="left" valign="bottom" colspan="5">All &lt;2 %.s<sup>–1</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean ± SEM, one-way ANOVA F test and corresponding exact p-value. n.s., not statistically different and ***: p&lt;0.001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Optogenetic stimulation induces a frequency-dependent, gradual increase in somatic calcium that precedes the vascular response</title><p>These observations raise the questions of how pyramidal neurons can induce vasoconstriction at higher AP-firing rates. It is generally accepted that the synthesis and/or release of vasodilatory substances requires an increase in intracellular Ca<sup>2+</sup> in the releasing cells (<xref ref-type="bibr" rid="bib3">Attwell et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Cauli and Hamel, 2010</xref>), but little is known about the release of vasoconstricting substances. We therefore determined whether an increase in somatic Ca<sup>2+</sup> concentration in cortical neurons was also dependent on photostimulation frequency. We combined optogenetic stimulation with whole-cell current clamp recording and intracellular Ca<sup>2+</sup> imaging using Rhod-2 delivered by patch pipette (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Excitation of this red Ca<sup>2+</sup> indicator at 585 nm did not induce any voltage response in the recorded pyramidal cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), as expected from the action spectrum of ChR2 (<xref ref-type="bibr" rid="bib48">Lin et al., 2009</xref>). In contrast, photostimulation at 470 nm elicited a train of spikes accompanied by a somatic Ca<sup>2+</sup> increase that decayed for tens of seconds after photostimulation without triggering any significant recurrent spiking activity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The Ca<sup>2+</sup> response evoked by 20 Hz photostimulation was more than twice of that evoked by 2 Hz photostimulation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; 2 Hz: ΔF/F<sub>0</sub>=34.5 ± 3.7 %, n=9 cells, vs. 20 Hz:ΔF/F<sub>0</sub>=79.5 ± 17.7 %, n=9 cells; t <sub>(16)</sub>=2.485, p=0.024397), while the average number of evoked spikes was about five times higher (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). These results demonstrate a frequency-dependent increase in intracellular Ca<sup>2+</sup> induced by photostimulation, that precedes vasoconstriction. We therefore aimed to understand the molecular mechanisms linking neuronal activity to vasoconstriction.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Photostimulation of pyramidal cells elicits a time-locked firing and a frequency-dependent calcium increase.</title><p>(<bold>A</bold>) Voltage response (top trace) and kinetics of relative fluorescence changes (red bottom trace) induced by photostimulation at 20 Hz. Insets, IR-DGC (top), Rhod2 fluorescence (bottom) pictures of an imaged layer II/III pyramidal cell. The somatic region of interest is outlined in white. Pial surface is upward. Scale bar: 20 µm. (<bold>B</bold>) Mean relative variations of Ca<sup>2+</sup> fluorescence in response to photostimulation at 2 Hz (grey, n=9 cells from 5 mice) and 20 Hz (black, n=9 cells from 5 mice). Dashed line represents the baseline. The vertical cyan bar indicates the duration of photostimulation. SEMs envelope the mean traces. Inset, Maximum increase in relative fluorescence changes induced immediately after photostimulation, indicated by the black arrow. The data are shown as the individual values and mean ± SEM. * statistically different with p&lt;0.05.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Somatic fluorescence measurements (A.U.) used to determine fluorescence changes in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig2-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Photostimulation of pyramidal cells does not evoke recurrent spiking network activity.</title><p>(<bold>A, B</bold>) Representative voltage responses evoked before, during, and after photostimulation (vertical cyan bars) delivered at 2 (<bold>A</bold>) and 20 Hz (<bold>B</bold>). The insets show the enlarged voltage responses during photostimulation (cyan zones). (<bold>C, D</bold>) Mean firing frequency of pyramidal cells evoked at 2 Hz (<bold>C</bold>), n=9 cells from 5 mice and 20 Hz (<bold>D</bold>), n=9 cells from 5 mice. Note sporadic action potentials after photostimulation. The insets show the zoomed-in mean firing frequency during the 40 s period around photostimulation. The dashed line represents the 0 Hz baseline. The SEMs envelope the mean traces.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Detection of spikes per second used to determine the mean firing frequency in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig2-figsupp1-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Vasoconstriction induced by pyramidal cells requires AP firing and is partially dependent on glutamatergic transmission</title><p>In pyramidal cells, APs induce both somatic Ca<sup>2+</sup> elevation (<xref ref-type="bibr" rid="bib81">Smetters et al., 1999</xref>) and glutamate release. To determine whether spiking activity is required for vasoconstriction induced by 20 Hz photostimulation, we blocked APs with the voltage-activated sodium channel blocker tetrodotoxin (TTX, 1 µM, n=6 arterioles). This treatment completely abolished the vasoconstriction evoked by 20 Hz photostimulation (<xref ref-type="fig" rid="fig3">Figure 3</xref>; AUC = 0.4 ± 0.4 x 10<sup>3</sup> %.s, t<sub>(14)</sub> = 5.57, p=8.6656 x 10<sup>–6</sup>). These data indicate that APs are mandatory for neurogenic vascular response and may involve glutamate release.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Optogenetically-induced vasoconstriction requires AP firing and partially glutamatergic transmission.</title><p>Effect of TTX (1 µM, brown, n=6 arterioles from 5 mice) and cocktail antagonists of AMPA/kainate (DNQX, 10 µM), NMDA (D-AP5, 50 µM), mGluR1 (LY367385, 100 µM) and mGluR5 (MPEP, 50 µM) receptors (gray, n=10 arterioles from 6 mice) on (<bold>A</bold>) kinetics and (<bold>B</bold>) magnitude of arteriolar vasoconstriction induced by 20 Hz photostimulation (cyan bar). The SEMs envelope the mean traces. Dashed lines represent the initial diameter. The shaded traces correspond to the kinetics of arteriolar vasoconstriction in control condition (<xref ref-type="fig" rid="fig1">Figure 1C</xref> – 20 Hz). Data are presented as the individual values and mean ± SEM. * and *** statistically different from control condition (<xref ref-type="fig" rid="fig1">Figure 1D</xref> – 20 Hz) with p&lt;0.05 and p&lt;0.001, respectively.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Basal network activity and tonic glutamate do not influence resting vascular tone.</title><p>(<bold>A, B</bold>) Kinetics of diameter changes (left panels) and comparison of the mean luminal diameter between the 5-min control period and after 15 or 20 min of treatment (right panels) with (<bold>A</bold>) TTX (1 µM, brown, n=4 arterioles from 2 mice) or (<bold>B</bold>) a cocktail of AMPA/kainate (DNQX, 10 µM), NMDA (D-AP5, 50 µM), mGluR1 (LY367385, 100 µM) and mGluR5 (MPEP, 50 µM) glutamate receptor antagonists (gray, n=10 arterioles from 6 mice). n.s. not statistically significant.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Indeed, high levels of glutamate released from pyramidal cells may activate NPY-expressing interneurons or astrocytes through activation of ionotropic or group I metabotropic glutamate receptors (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Mulligan and MacVicar, 2004</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). It may also directly activate NMDA receptors on arteriolar smooth muscle cells, resulting in a large intracellular Ca<sup>2+</sup> increase and subsequent vasoconstriction (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>). To test the hypothesis that glutamate from pyramidal cells, either directly or indirectly, results in vasoconstriction, we blocked glutamatergic transmission by antagonizing AMPA/kainate, NMDA and group I metabotropic receptors expressed by cortical neurons (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>) and juvenile astrocytes (<xref ref-type="bibr" rid="bib85">Sun et al., 2013</xref>). Glutamate receptor antagonists reduced the magnitude of vasoconstriction (–1.6±0.4 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 3.28, p=0.0160) by approximately half (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Taken together, our data suggest that photostimulation of pyramidal cells elicits a frequency-dependent vasoconstriction that requires AP firing and partially involves glutamatergic transmission. We therefore sought to elucidate the glutamate-independent vasoactive pathway underlying this neurogenic vascular response.</p></sec><sec id="s2-4"><title>Pyramidal cells express the mRNAs for a cell autonomous PGE2 and PGF2α synthesis</title><p>Several arachidonic acid metabolites produced after intracellular Ca<sup>2+</sup> elevation, including PGF2α, but also PGE2, exert dose-dependent vasoconstrictive effects (<xref ref-type="bibr" rid="bib19">Dabertrand et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rosehart et al., 2021</xref>; <xref ref-type="bibr" rid="bib105">Zonta et al., 2003</xref>). These prostaglandins could therefore be progressively released as the frequency of photostimulation and somatic Ca<sup>2+</sup> increase and thereby promote vasoconstriction. Layer II-III pyramidal cells have been shown to produce PGE2 (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>). To determine whether the synthesizing enzymes of PGE2 and PGF2αare present in pyramidal cells, we performed single-cell RT-PCR after patch-clamp recording (<xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref>). Sixteen layer II-III pyramidal cells were visually identified based on the triangular shape of their soma and a prominent apical dendrite. Their glutamatergic phenotype was confirmed both by their stereotypical regular spiking firing pattern (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and also by the expression of the vesicular glutamate transporter, vGlut1, and neither of the two GABA synthesizing enzymes, thus excluding possible contamination by GABAergic interneurons (<xref ref-type="fig" rid="fig4">Figure 4B</xref>; <xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref>). The rate-limiting enzymes of prostaglandin synthesis, cyclooxygenase-1 (COX-1) and –2 (COX-2), were detected in 25% (n=4 of 16 cells) and 31% (n=5 of 16 cells) of pyramidal cells, respectively, (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>) but were never co-expressed (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Although the differential expression of COX-1 or COX-2 allowed the definition of three non-overlapping molecular subpopulations of pyramidal cells, they did not show distinctive electrophysiological features (<xref ref-type="table" rid="table2">Table 2</xref>). The cytosolic enzyme responsible for synthesizing PGE2 (cPGES) was observed in most pyramidal cells (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>; 88%, n=14 of 16 cells). In addition, the microsomal PGES, mPGES1 and mPGES2 were detected in 6% (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, n=1 of 16 cells) and 38% (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>; n=6 of 16 cells) of pyramidal cells, respectively, and were always co-expressed with cPGES. The PGF2α terminal-synthesizing enzyme AKR1B3 was observed in the majority of neurons (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>; n=11 of 16 cells, 69%). Occasionally, it was co-detected with the prostamide/prostaglandin F synthase (PM-PGFS, <xref ref-type="fig" rid="fig4">Figure 4C</xref>, n=5 of 16 cells, 31%) and the PGE2 converting enzyme carbonyl reductase 1 (CBR1, <xref ref-type="fig" rid="fig4">Figure 4C</xref>; n=3 of 16 cells, 19%). CBR1 was consistently detected alongside at least one PGES. Pyramidal cells positive for COX-1 also expressed PGES (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), with most of them also co-expressing PGFS (n=3 out of 4). All neurons positive for COX-2 co-expressed both PGES and PGFS (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These molecular observations suggest that subpopulations accounting for about half of layer II-III pyramidal cells express all the transcripts necessary for the synthesis of PGE2 and PGF2α.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Layer II-III pyramidal cells express PGE2 and PGF2α synthesizing enzymes.</title><p>(<bold>A</bold>) Voltage responses of a layer II-III pyramidal cell induced by injection of current (bottom traces). In response to a just-above-threshold current pulse, the neuron fired long-lasting action potentials with little frequency adaptation (middle black trace). Near saturation, it exhibits the pronounced spike amplitude accommodation and marked frequency adaptation characteristic of regular spiking cells (upper grey trace). (<bold>B</bold>) Agarose gel analysis of the scRT-PCR products of the pyramidal cell shown in (<bold>A</bold>) revealing expression of vGluT1, COX-2, mPGES2, cPGES, PM-PGFS and CBR1. Φx174 digested by <italic>HaeIII</italic> (Φ in bps) was used as molecular weight marker (<bold>C</bold>) Histogram summarizing the single-cell detection rate of PGE2 and PGf2α synthesizing enzymes in layer II-III pyramidal cells (n=16 cells from 6 mice). PGES (green zone) corresponds to mPGES1, mPGES2 and/or cPGES and PGFS (blue zone) to PM-PGFS, CBR1 and/or AKR1B3. (<bold>D</bold>) Co-expression of PGE2 and PGf2α synthesizing enzymes in pyramidal cells. The box size is proportional to the detection rate. Note the absence of co-expression between COX-1 (purple) and COX-2 (red). Co-expression of a PGES (left, green) and a PGFS (right, blue) with COX-1 (up) and COX-2 (bottom).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original files of the full raw unedited gels shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102424-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Uncropped gels shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref> with relevant lanes labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102424-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Sensitivity of the RT-mPCR protocol.</title><p>Agarose gel analysis of a RT-PCR performed from 500 pg of forebrain total RNAs Φx174 digested by <italic>HaeIII</italic> (Φ in bps) was used as molecular weight marker. All the amplicons were detected with the expected sized from the gene sequences (Appendix 1—key resources table).</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original file of the full raw unedited gel shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102424-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Uncropped gels shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> with relevant lanes labeled.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-102424-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig4-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Electrophysiological properties of pyramidal cells recorded during single-cell RT-PCR experiments.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Electrophysiological and molecular properties of pyramidal cells used for <xref ref-type="table" rid="table2">Table 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-table2-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">COXs-negative(n=7)</th><th align="left" valign="bottom">COX-1 positive(n=4)</th><th align="left" valign="bottom">COX-2 positive(n=5)</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="3"><bold>Passive properties</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Resting potential (mV)</td><td align="left" valign="bottom">–82.0±2.2</td><td align="left" valign="bottom">–84.7±4.2</td><td align="left" valign="bottom">–82.0±6.1</td></tr><tr><td align="left" valign="bottom">Input resistance (MΩ)</td><td align="left" valign="bottom">329±53.7</td><td align="left" valign="bottom">360.8±63.7</td><td align="left" valign="bottom">314.2±79.7</td></tr><tr><td align="left" valign="bottom">Time constant (ms)</td><td align="left" valign="bottom">50.7±6.4</td><td align="left" valign="bottom">47.3±7.2</td><td align="left" valign="bottom">47.74±10.1</td></tr><tr><td align="left" valign="bottom">Membrane capacitance (pF)</td><td align="left" valign="bottom">161.4±14.7</td><td align="left" valign="bottom">133.2±7.8</td><td align="left" valign="bottom">159.4±23.0</td></tr><tr><td align="left" valign="bottom">Sag index (%)</td><td align="left" valign="bottom">11.3±3.8</td><td align="left" valign="bottom">6.7±1.1</td><td align="left" valign="bottom">6.9±1.8</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Just above threshold properties</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Rheobase (pA)</td><td align="left" valign="bottom">52.7±8.7</td><td align="left" valign="bottom">51.7±15.5</td><td align="left" valign="bottom">62.3±18.2</td></tr><tr><td align="left" valign="bottom">First spike latency (ms)</td><td align="left" valign="bottom">295.2±50.8</td><td align="left" valign="bottom">271.6±62.9</td><td align="left" valign="bottom">178.7±55.6</td></tr><tr><td align="left" valign="bottom">Adaptation (Hz/s)</td><td align="left" valign="bottom">–3.1±0.9</td><td align="left" valign="bottom">–2.6±0.3</td><td align="left" valign="bottom">–3.3±1.3</td></tr><tr><td align="left" valign="bottom">Minimal frequency (Hz)</td><td align="left" valign="bottom">5.5±0.7</td><td align="left" valign="bottom">4.6±0.4</td><td align="left" valign="bottom">6.3±1.2</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Firing properties</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Accommodation (mV)</td><td align="left" valign="bottom">16.4±4.6</td><td align="left" valign="bottom">24.8±4.9</td><td align="left" valign="bottom">11.9±3.7</td></tr><tr><td align="left" valign="bottom">Amplitude of early adaptation (Hz)</td><td align="left" valign="bottom">62.1±13.3</td><td align="left" valign="bottom">89.8±8.5</td><td align="left" valign="bottom">62.3±16.4</td></tr><tr><td align="left" valign="bottom">Time constant of early adaptation (ms)</td><td align="left" valign="bottom">29.7±4.4</td><td align="left" valign="bottom">28.3±2.2</td><td align="left" valign="bottom">43.1±18.7</td></tr><tr><td align="left" valign="bottom">Late adaptation (Hz/s)</td><td align="left" valign="bottom">–11.6±2.3</td><td align="left" valign="bottom">–9.6±3.9</td><td align="left" valign="bottom">–10.7±1.7</td></tr><tr><td align="left" valign="bottom">Maximal frequency (Hz)</td><td align="left" valign="bottom">23.4±1.7</td><td align="left" valign="bottom">27.6±3.3</td><td align="left" valign="bottom">22.0±2.9</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Action potentials properties</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike amplitude (mV)</td><td align="left" valign="bottom">94.8±1.7</td><td align="left" valign="bottom">93.0±5.0</td><td align="left" valign="bottom">88.6±1.9</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike duration (ms)</td><td align="left" valign="bottom">1.8±0.1</td><td align="left" valign="bottom">1.9±0.1</td><td align="left" valign="bottom">1.8±0.1</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike amplitude (mV)</td><td align="left" valign="bottom">91.6±1.9</td><td align="left" valign="bottom">91.9±4.5</td><td align="left" valign="bottom">85.5±2.5</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike duration (ms)</td><td align="left" valign="bottom">1.9±0.1</td><td align="left" valign="bottom">1.9±0.1</td><td align="left" valign="bottom">1.9±0.1</td></tr><tr><td align="left" valign="bottom">Amplitude Reduction (%)</td><td align="left" valign="bottom">3.4±0.4</td><td align="left" valign="bottom">1.1±0.7</td><td align="left" valign="bottom">3.6±1.4</td></tr><tr><td align="left" valign="bottom">Duration Increase (%)</td><td align="left" valign="bottom">5.3±0.9</td><td align="left" valign="bottom">3.8±1.5</td><td align="left" valign="bottom">7.5±1.6</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>AHP and ADP properties</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike fast AHP (mV)</td><td align="left" valign="bottom">–8.7±0.8</td><td align="left" valign="bottom">–8.7±0.6</td><td align="left" valign="bottom">–7.9±1.1</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike ADP (mV)</td><td align="left" valign="bottom">0.2±0.1</td><td align="left" valign="bottom">0.2±0.2</td><td align="left" valign="bottom">0±0</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike medium AHP (mV)</td><td align="left" valign="bottom">–13.8±1.4</td><td align="left" valign="bottom">–15.5±0.6</td><td align="left" valign="bottom">–13.7±0.8</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike fast AHP latency (ms)</td><td align="left" valign="bottom">8.2±1.0</td><td align="left" valign="bottom">7.7±1.4</td><td align="left" valign="bottom">9.8±1.5</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike ADP latency (ms)</td><td align="left" valign="bottom">4.6±2.2</td><td align="left" valign="bottom">2.0±2.0</td><td align="left" valign="bottom">0±0</td></tr><tr><td align="left" valign="bottom">1<sup>st</sup> spike, medium AHP latency (ms)</td><td align="left" valign="bottom">49.2±3.3</td><td align="left" valign="bottom">48.2±5.4</td><td align="left" valign="bottom">54.8±6.1</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike fast AHP (mV)</td><td align="left" valign="bottom">–9.8±1.1</td><td align="left" valign="bottom">–8.5±0.5</td><td align="left" valign="bottom">–9.6±1.0</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike ADP (mV)</td><td align="left" valign="bottom">0±0</td><td align="left" valign="bottom">0.1±0.1</td><td align="left" valign="bottom">0±0</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike medium AHP (mV)</td><td align="left" valign="bottom">–16.1±1.2</td><td align="left" valign="bottom">–17.1±0.6</td><td align="left" valign="bottom">–15.8±0.4</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike, fast AHP latency (ms)</td><td align="left" valign="bottom">8.6±0.9</td><td align="left" valign="bottom">7.1±0.7</td><td align="left" valign="bottom">11.7±1.3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="3">F (2.13)=4.063<break/>p=0.0426</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="3">*</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="3">No significant difference in multiple comparisons.</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike ADP latency (ms)</td><td align="left" valign="bottom">1.2±1.2</td><td align="left" valign="bottom">1.7±1.7</td><td align="left" valign="bottom">0±0</td></tr><tr><td align="left" valign="bottom">2<sup>nd</sup> spike, medium AHP latency (ms)</td><td align="left" valign="bottom">57.1±5.8</td><td align="left" valign="bottom">51.9±4.6</td><td align="left" valign="bottom">58.3±6.7</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as mean ± SEM. Statistical analyses were performed using a one-way ANOVA (F test) or a Kruskal-Wallis test, depending on the result of the Shapiro-Wilk normality test. If a significant result was found, the corresponding statistics are reported, and post-hoc multiple comparisons are performed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Prostaglandins underpin vasoconstriction ex vivo and in vivo</title><p>To investigate whether prostaglandins could mediate neurogenic vasoconstriction, we inhibited their synthesis. In cortical slices, the non-selective COX inhibitor indomethacin (5 µM, <xref ref-type="table" rid="table3">Table 3</xref>, <xref ref-type="fig" rid="fig5">Figure 5A and B</xref>) completely abolished the vascular response (n=10 arterioles, AUC = 0.0 ± 0.2 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 5.86, <italic>P</italic>=3.4385 x 10<sup>–5</sup>). To verify that high-frequency stimulation of pyramidal cells also induces vasoconstriction in vivo, 10 Hz photostimulation was reproduced in anesthetized Emx1-cre;Ai32 mice. Pial arterioles diameter measured by two-photon line-scan imaging (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>) revealed that pyramidal cells induce vasodilation (1st phase) followed by sustained vasoconstriction (2nd phase, <xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). The constriction phase was inhibited by indomethacin (injected intravenously (i.v.)), indicating the involvement of prostaglandins in the vasoconstriction (AUC<sub>Ctrl</sub> = <sub>-</sub>291.5 ± 92.4 %.s vs. AUC<sub>Indo</sub>.=332.4 ± 184.4 %.s, U<sub>(5,4)</sub> = 0, p=0.0159, <xref ref-type="fig" rid="fig5">Figure 5D–F</xref>), which confirms our ex vivo observations. To determine whether they originated from COX-1 or COX-2 activity, we utilized selective inhibitors in cortical slices. The vasoconstriction magnitude was reduced by the COX-1 inhibitor SC-560 (100 nM, <xref ref-type="table" rid="table3">Table 3</xref>, n=10 arterioles, –1.4±0.7 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 3.54, p=9.3396 x 10<sup>–3</sup>, <xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). The COX-2 inhibitor NS-398 (10 µM, <xref ref-type="table" rid="table3">Table 3</xref>, n=7 arterioles) completely abolished pyramidal cell-induced vasoconstriction in a more potent manner (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>; AUC = 0.1 ± 0.3 x 10<sup>3</sup> %.s, t<sub>(15)</sub> = 5.45, p=1.0853 x 10<sup>–5</sup>), mimicking the ex vivo effect of indomethacin. These observations suggest that prostaglandins, derived mainly from COX-2 activity, and to a lesser extent from COX-1 activity, mediate pyramidal cell-induced vasoconstriction.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>GE2 mostly derived from COX-2 activity and its EP1 and EP3 receptors mediates vasoconstriction induced by optogenetically activated pyramidal cells.</title><p>(<bold>A, B</bold>) Ex vivo effects of the COX1/2 inhibitor indomethacin (magenta, n=10 arterioles from 9 mice), the COX-1 inhibitor SC-560 (purple, n=10 arterioles from 7 mice), and the COX-2 inhibitor NS-398 (red, n=7 arterioles from 6 mice) on kinetics (<bold>A</bold>) and AUC (<bold>B</bold>) of arteriolar vasoconstriction induced by 20 Hz photostimulation (vertical cyan bar). In vivo experiments are highlighted by a black frame. (<bold>C</bold>) Optogenetic stimulation was achieved in vivo with an optic fiber through a chronic cranial window over the barrel cortex. (<bold>D</bold>) Left, diameter of pial arterioles labeled with fluorescein dextran (i.v) was measured with line-scan crossing the vessel (white line). Right, Representative examples of vascular response upon photostimulation (10 Hz, 10 s) under control (top) and indomethacin condition (bottom). (<bold>E</bold>) Diameter changes upon photostimulation under control (black; n=5 arterioles, 4 mice) or indomethacin (magenta; n=4 arterioles, 4 mice) conditions. (<bold>F</bold>) Area under the curve of the diameter change in control (black) or indomethacin (magenta) conditions calculated between 20 and 40 s (unpaired, two-tailed Mann Whitney test, * p&lt;0.05). (<bold>G, H</bold>) Effects of the EP1, EP3 and FP antagonists, ONO-8130 (10 nM, dark green, n=9 arterioles from 7 mice), L798,106 (1 µM, light green, n=9 arterioles from 5 mice) and AL8810 (10 µM, dark blue, n=9 arterioles from 7 mice), respectively, on kinetics (<bold>G</bold>) and AUC (<bold>H</bold>) of arteriolar vasoconstriction induced by 20 Hz photostimulation. The data are shown as the individual values and mean ± SEM. Dashed line represents the baseline. The SEMs envelope the mean traces. The shaded traces in A and G correspond to the control condition (from <xref ref-type="fig" rid="fig1">Figure 1C</xref> – 20 Hz). *, ** and *** statistically different from 20 Hz control condition with p&lt;0.05, 0.01 and 0.001, respectively.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig5">Figure 5A, B, G and H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Diameter changes of individual arterioles shown in <xref ref-type="fig" rid="fig5">Figure 5E</xref> under control condition.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig5-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Diameter changes of individual arterioles shown in <xref ref-type="fig" rid="fig5">Figure 5E</xref> after indomethacin treatment.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Tonic PGE2 does not affect basal vascular tone.</title><p>Kinetics of diameter changes (left panels) and comparison of the mean luminal diameter between the five minutes control period and the five minutes following 30 min treatment by the COX inhibitors (<bold>A</bold>) indomethacin (5 µM, magenta, n=8 arterioles from 7 mice), (<bold>B</bold>) SC-560 (100 nM, purple, n=10 arterioles from 7 mice), (<bold>C</bold>) NS-398 (10 µM, red, n = 5 arterioles from 4 mice), and the EP1, EP3 and FP antagonists (<bold>D</bold>) ONO-8130 (10 nM, dark green, n = 9 arterioles from 7 mice), (<bold>E</bold>) L-798,106 (1 µM, light green, n = 9 arterioles from 4 mice) and (<bold>F</bold>) AL8810 (10 µM, dark blue, n = 9 arterioles from 7 mice), respectively. n.s. not statistically significant and * statistically different with p&lt; 0.05.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig5-figsupp1-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>PGE2 dose-dependently induces vasoconstriction<bold>.</bold></title><p>(<bold>A, B</bold>) Kinetics of arteriolar diameter changes induced by exogenous application of PGE2 (vertical green zones) at (<bold>A1</bold>) 10 nM (n = 7 arterioles from 4 mice), (<bold>A2</bold>) 100 nM (n=8 arterioles from 6 mice), (<bold>A3</bold>) 1 µM (n=7 arterioles from 4 mice) and (<bold>A4</bold>) 10 µM (n=6 arterioles from 4 mice), by (<bold>B</bold>) the EP1/EP3 agonist sulprostone (fluorescent green, 10 µM, n=8 arterioles from 5 mice) or (<bold>C</bold>) by 10 µM PGE2 under a TTX application (1 µM, n=5 arterioles from 3 mice). Dashed line represents the baseline. The SEMs envelope the mean traces. (<bold>D</bold>) Dose-dependent effect of PGE2 or sulprostone effect on AUC of vascular responses. The data are shown as the individual values and mean ± SEM.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig5-figsupp2-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig5-figsupp2-v1.tif"/></fig></fig-group><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>IC<sub>50</sub> and concentrations of inhibitors, blocker and antagonists used in tissue.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="2">Concentrations used for inhibition/antagonism</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Inhibitor/antagonist</bold></td><td align="left" valign="bottom"><bold>In vitro IC<sub>50</sub></bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Preparation</bold></td><td align="left" valign="bottom"><bold>Concentration</bold></td></tr><tr><td align="left" valign="bottom">Indomethacin</td><td align="left" valign="bottom">COX-1: 22 nM; <xref ref-type="bibr" rid="bib49">Lora et al., 1998</xref></td><td align="left" valign="bottom">COX-2: 87 nM</td><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref></td><td align="left" valign="bottom">5 µM</td></tr><tr><td align="left" valign="bottom">SC560</td><td align="left" valign="bottom">COX-1: 9 nM; <xref ref-type="bibr" rid="bib82">Smith et al., 1998</xref></td><td align="left" valign="bottom">COX-2: 6.3 µM</td><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref></td><td align="char" char="." valign="bottom">100 nM</td></tr><tr><td align="left" valign="bottom">NS-398</td><td align="left" valign="bottom">COX-1: 50 µM; <xref ref-type="bibr" rid="bib49">Lora et al., 1998</xref></td><td align="left" valign="bottom">COX-2: 0.6 µM</td><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref></td><td align="left" valign="bottom">10 µM</td></tr><tr><td align="left" valign="bottom">ONO-8130</td><td align="left" valign="bottom">EP1 receptors: 9.3 nM; <xref ref-type="bibr" rid="bib73">Säfholm et al., 2013a</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">isolated guinea pig trachea; <xref ref-type="bibr" rid="bib74">Säfholm et al., 2013b</xref></td><td align="char" char="." valign="bottom">10 nM</td></tr><tr><td align="left" valign="bottom">L798,106</td><td align="left" valign="bottom">EP3 receptors: 0.3 nM (Ki); <xref ref-type="bibr" rid="bib39">Juteau et al., 2001</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated mouse mesenteric arteries; <xref ref-type="bibr" rid="bib16">Chia et al., 2011</xref></td><td align="left" valign="bottom">1 µM</td></tr><tr><td align="left" valign="bottom">AL8810</td><td align="left" valign="bottom">FP receptors: 426 nM (Ki); <xref ref-type="bibr" rid="bib32">Griffin et al., 1999</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Isolated porcine retinal arterioles; <xref ref-type="bibr" rid="bib58">Oversø Hansen et al., 2015</xref></td><td align="left" valign="bottom">10 µM</td></tr><tr><td align="left" valign="bottom">Paxilline</td><td align="left" valign="bottom">BK channels: 97 nM; <xref ref-type="bibr" rid="bib88">Tammaro et al., 2004</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref></td><td align="left" valign="bottom">1 µM</td></tr><tr><td align="left" valign="bottom">HET-0016</td><td align="left" valign="bottom">CYP4A isoforms: 35 nM; <xref ref-type="bibr" rid="bib54">Miyata et al., 2001</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib8">Blanco et al., 2008</xref></td><td align="char" char="." valign="bottom">100 nM</td></tr><tr><td align="left" valign="bottom">BIBP3226</td><td align="left" valign="bottom">Y1 receptors: 26 nM; <xref ref-type="bibr" rid="bib68">Rudolf et al., 1994</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mouse brain slices; <xref ref-type="bibr" rid="bib84">Sun et al., 2003</xref></td><td align="left" valign="bottom">1 µM</td></tr></tbody></table></table-wrap></sec><sec id="s2-6"><title>PGE2 mediates vasoconstriction by acting primarily on EP1 receptor</title><p>To determine the nature of the prostaglandins and their receptors, we selectively antagonized the vasoconstrictor receptors of PGE2, EP1 or EP3, or the FP receptor of PGF2α. The magnitude of vasoconstriction was reduced by the selective EP1 receptor antagonist ONO-8130 (10 nM, <xref ref-type="table" rid="table3">Table 3</xref>, n=9 arterioles, <xref ref-type="fig" rid="fig5">Figure 5G and H</xref>, 0.3±0.3 x 10<sup>3</sup> %.s, t<sub>(17)</sub> = 6.01, p=2.8451 x 10<sup>–6</sup>), and to a lesser extent, by the EP3 receptor antagonist L-798,106 (1 µM, <xref ref-type="table" rid="table3">Table 3</xref>, n=9 arterioles, <xref ref-type="fig" rid="fig5">Figure 5G and H</xref>, –0.9±0.4 x 10<sup>3</sup> %.s, t<sub>(17)</sub> = 4.30, p=8.0261 x 10<sup>–4</sup>). Impairing FP receptor signaling with AL-8810 (10 µM, <xref ref-type="table" rid="table3">Table 3</xref>, n=9 arterioles, <xref ref-type="fig" rid="fig5">Figure 5G and H</xref>) tended to reduce the evoked vasoconstriction, however, it did not reach statistical significance (AUC = –1.9 ± 0.4 x 10<sup>3</sup> %.s, t<sub>(17)</sub> = 2.82, p=0.0533). Additionally, the pre-constricted state induced by this weak partial FP agonist (<xref ref-type="bibr" rid="bib79">Sharif and Klimko, 2019</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>) resulted in a diameter reduction of approximately 4% (diameter before application 21.8±2.5 µm vs. during 20.9±2.6 µm, n=9 arterioles, t<sub>(8)</sub> = 2.374, p=0.0457, paired t-test), which underestimated the optogenetic vascular response. Taken together, these results indicate that pyramidal cell photoactivation induces vasoconstriction through the release of PGE2 originating mainly from COX-2. This effect primarily acts on the EP1 receptor and, to a lesser extent, on the EP3 receptor.</p><p>To test a direct effect of PGE2 through vascular EP1/EP3 activation, we determined whether exogenous agonists of PGE2 receptors could mimic the vasoconstriction induced by pyramidal cell photostimulation. Similar to increasing photostimulation frequencies, exogenous application of PGE2 induced vasoconstriction in a dose-dependent manner which persisted for several minutes after removal (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A and D</xref>). Likewise, 10 µM sulprostone, an EP1/EP3 agonist with an EC<sub>50</sub> comparable to that of PGE2 (<xref ref-type="bibr" rid="bib9">Boie et al., 1997</xref>), mimicked the vasoconstriction induced by 1–10 µM PGE2 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Application of 10 µM PGE2 in the presence of TTX did not impair the evoked vasoconstriction (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). These observations suggest that PGE2 and its EP1 and EP3 receptors mediate a sustained neurogenic vasoconstriction and that once PGE2 is released, its constrictive effect is independent of AP firing.</p></sec><sec id="s2-7"><title>Astrocytes through 20-HETE and NPY interneurons are indirect intermediates of pyramidal cell-induced vasoconstriction</title><p>In addition to smooth muscle cells, PGE2 released by pyramidal cells can also activate astrocytes and neurons (<xref ref-type="bibr" rid="bib18">Clasadonte et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Di Cesare et al., 2006</xref>), which also express its receptors (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>). To assess whether astrocytes could mediate the PGE2-dependent vasoconstriction, we first targeted the large conductance Ca<sup>2+</sup>-activated (BK) channels and the 20-HETE pathways, both of which mediate astrocyte-derived vasoconstriction dependent on glutamatergic transmission (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Mulligan and MacVicar, 2004</xref>). Blockade of BK channels with paxilline (1 µM, <xref ref-type="table" rid="table3">Table 3</xref>, n=10 arterioles) did not impair the vascular response (<xref ref-type="fig" rid="fig6">Figure 6</xref>; AUC = –3.7 ± 0.3 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 0.03, p=1). Selective inhibition of the 20-HETE synthesizing enzyme, CYP450 ω-hydroxylase, with HET-0016 (100 nM, n=10 arterioles, <xref ref-type="table" rid="table3">Table 3</xref>) reduced the magnitude of the evoked vasoconstriction (<xref ref-type="fig" rid="fig6">Figure 6</xref>; AUC = –1.6 ± 0.7 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 3.32, p=0.0160). These data suggest that astrocytes partially mediate the vasoconstriction induced by pyramidal cells via 20-HETE but not via K<sup>+</sup> release. We next determined whether NPY, a potent vasoconstrictor (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>), was involved in neurogenic vasoconstriction. Antagonism of the NPY Y1 receptors by BIBP3226 (1 µM, <xref ref-type="table" rid="table3">Table 3</xref>, n=10 arterioles) abolished neurogenic vasoconstriction (<xref ref-type="fig" rid="fig6">Figure 6</xref>; AUC = –0.3 ± 0.2 x 10<sup>3</sup> %.s, t<sub>(18)</sub> = 5.28, p=1.9512 x 10<sup>–5</sup>). These results suggest that neurogenic vasoconstriction induced by pyramidal cell photostimulation involves NPY release and the activation of Y1 receptors (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>; <xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>) and astrocytes via 20-HETE in a glutamatergic-dependent and -independent manner.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>NPY Y1 receptors activation and 20-HETE synthesis mediates the vasoconstriction induced by pyramidal neurons.</title><p>Effects of paxilline (1 µM, orange, n=10 arterioles from 6 mice), HET-0016 (100 nM, blue-grey, n=10 arterioles from 7 mice) and BIBP3226 (1 µM, yellow, n=10 arterioles from 6 mice) on (<bold>A</bold>) kinetics and (<bold>B</bold>) AUC of arteriolar vasoconstriction induced by 20 Hz photostimulation (vertical blue bar). Dashed line represents the baseline. The SEMs envelope the mean traces. The shaded traces correspond to the control condition (<xref ref-type="fig" rid="fig1">Figure 1C</xref> – 20 Hz). The data are shown as the individual values and mean ± SEM. * and *** statistically different from 20 Hz control condition with p&lt;0.05 and 0.001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102424-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Vasoconstrictive pathways do not influence resting vascular tone.</title><p>Kinetics of diameter changes (left panels) and comparison of the mean luminal diameter between the five-minute control period and the last five minutes (right panels) of treatment with (<bold>A</bold>) paxilline (1 µM, orange, n=5 arterioles from 3 mice) for five minutes or with (<bold>B</bold>) HET-0016 (100 nM, blue-grey, n = 10 arterioles from 7 mice) or (<bold>C</bold>) BIBP3226 (1 µM, yellow, n=10 arterioles from 6 mice) for 30 min. n.s. not statistically significant.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Diameter measurements (µm) of individual arterioles used to determine diameter changes in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-102424-fig6-figsupp1-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig6-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study establishes that pyramidal cell activity leads to arteriolar vasoconstriction, and that the magnitude of the vasoconstriction depends on AP firing frequency and correlates with a graded increase in pyramidal cell somatic Ca<sup>2+</sup>. This vascular response partially involves glutamatergic transmission through direct and indirect mechanisms on arteriolar smooth muscle cells. Ex vivo and in vivo observations revealed that PGE2, predominantly produced by layer II-III COX-2 pyramidal cells, and its EP1 and EP3 receptors play a crucial role in neurogenic vasoconstriction. Pharmacological evidence indicates that some interneurons, via NPY release and activation of Y1 receptors, and to a lesser extent, astrocytes through 20-HETE and possibly COX-1 derived PGE2 play an intermediary role in this process (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Possible pathways of vasoconstriction induced by pyramidal neurons.</title><p>20 Hz photostimulation induces activation of pyramidal neurons expressing channelrhodopsin-2 (ChR2<sub>H134R</sub>) and increases intracellular calcium (Ca<sup>2+</sup>). Arachidonic acid (AA) is released from membrane phospholipids (MPL) by phospholipases (PL) activated by intracellular Ca<sup>2+</sup> and is metabolized by type-1 and type-2 cyclooxygenases (COX-1 and COX-2) and prostaglandin E2 synthases (PGES) to produce prostaglandin E2 (PGE2). Three non-exclusive pathways can be proposed for arteriolar vasoconstriction in layer I: (1) PGE2 released into the extracellular space may act directly on arteriolar EP1 and EP3 receptors to induce smooth muscle cell constriction. (2) Glutamate released from pyramidal cells may activate neuropeptide Y (NPY) interneurons and NPY is released to act on vascular and neuronal Y1 receptors to constrict smooth muscle cells and promote glutamate release, respectively. Glutamate can also activate astrocytes to induce constriction through the 20-HETE and the COX-1/PGE2 pathways. (3) PGE2 may act on pre- and postsynaptic EP2 receptors to facilitate glutamate release and NPY interneuron activation, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-fig7-v1.tif"/></fig><p>We found that increasing the frequency of photostimulation in an ex vivo preparation caused nearby arteriole to go from a barely discernible response to robust vasoconstriction. In contrast, in vivo observations in anesthetized animals, with slower NVC compared to awake animals (<xref ref-type="bibr" rid="bib71">Rungta et al., 2021</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>), have shown that the optogenetic stimulation of pyramidal cells results in a biphasic response: a fast hyperemic/vasodilatory response (<xref ref-type="bibr" rid="bib40">Kahn et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Scott and Murphy, 2012</xref>), which can be followed by a pronounced vasoconstriction (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). The slow kinetics of the vascular response observed ex vivo is comparable with previous observations in slices (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>; <xref ref-type="bibr" rid="bib65">Rancillac et al., 2006</xref>), and is likely due to the lower recording temperature compared to in vivo, which slows the synthesis of vasoactive mediators (<xref ref-type="bibr" rid="bib65">Rancillac et al., 2006</xref>) and downstream reactions. The difficulty in observing vasodilation in cortical slices may be due to relaxed arterioles which favor vasoconstriction (<xref ref-type="bibr" rid="bib8">Blanco et al., 2008</xref>). The evidence that neurogenic vasoconstriction is frequency-dependent (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and that pharmacologically induced vasoconstriction persists in preconstructed (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>) or pressurized arterioles (<xref ref-type="bibr" rid="bib19">Dabertrand et al., 2013</xref>), suggests that the neurogenic vasoconstriction primarily depends on a high pyramidal cell firing rate rather than on vascular tone.</p><p>Most previous observations did not report a decreased in CBF induced by optogenetic stimulation of pyramidal cells in vivo (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Scott and Murphy, 2012</xref>). This may be attributed to differences in the photostimulation paradigm and/or the specific subtype of pyramidal cells that were stimulated. In our study, we used 10 s of photostimulation both in vivo and ex vivo. Earlier studies have employed shorter photostimulation times, lasting no more than 1 s (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Scott and Murphy, 2012</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>), which may have resulted in an insufficient number of elicited APs to induce robust vasoconstriction. Furthermore, we observed that neurogenic vasoconstriction is highly dependent on COX-2, which is primarily expressed in layer II-III pyramidal cells (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>). In our study, photostimulation of almost all pyramidal cells in Emx1-Cre;Ai32 mice (<xref ref-type="bibr" rid="bib31">Gorski et al., 2002</xref>; <xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>) likely resulted in the release of more COX-2 metabolites. Thy1-ChR2 mice used in previous studies (<xref ref-type="bibr" rid="bib78">Scott and Murphy, 2012</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>), on the other hand, express primarily ChR2 in layer V pyramidal cells (<xref ref-type="bibr" rid="bib40">Kahn et al., 2013</xref>) which more rarely express COX-2.</p><p>Our ex vivo and in vivo observations revealed that PGE2, primarily derived from COX-2, plays a critical role in neurogenic vasoconstriction by activating EP1 and EP3 receptors expressed by vascular smooth muscle cells (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>). Previous studies have shown that COX-2 pyramidal cells, when activated in vivo by sensory stimulation or ex vivo, induce a NMDA-dependent increase in CBF and vasodilation through PGE2 and EP2/EP4 receptors (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Lecrux et al., 2011</xref>; <xref ref-type="bibr" rid="bib56">Niwa et al., 2000</xref>). Differences in the levels and/or sites of action of released PGE2 may explain the absence of secondary vasoconstriction. In Emx1-Cre;Ai32 mice (<xref ref-type="bibr" rid="bib31">Gorski et al., 2002</xref>; <xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>), optogenetic stimulation may have activated a greater number of COX-2 pyramidal cells and resulted in a higher local release of PGE2 compared to sensory stimulation. Furthermore, since PGE2 is barely catabolized in the cerebral cortex (<xref ref-type="bibr" rid="bib1">Alix et al., 2008</xref>), most of its removal occurs across the blood-brain barrier by specific transporters. The lack of blood perfusion in brain slices may impair this clearance mechanism, leading to PGE2 accumulation. It is noteworthy that the PGE2-induced vasoconstriction persisted after its removal (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). A high level of PGE2 may have facilitated the activation of the EP1 receptor, which has a lower affinity than the EP2/EP4 receptors (<xref ref-type="bibr" rid="bib9">Boie et al., 1997</xref>). Additionally, it may have promoted the rapid desensitization of the dilatory EP4 receptor (<xref ref-type="bibr" rid="bib20">Desai et al., 2000</xref>) thereby favoring vasoconstriction. Furthermore, PGE2 can induce either EP1-dependent arteriolar dilation or constriction depending on whether it is locally applied to capillaries or arterioles. Constriction prevails when both segments are exposed (<xref ref-type="bibr" rid="bib67">Rosehart et al., 2021</xref>). Our photostimulation focused on superficial penetrating arterioles, which lack a capillary network in their close vicinity (<xref ref-type="bibr" rid="bib43">Kasischke et al., 2011</xref>). This may have facilitated the direct EP1-mediated arteriolar constriction (<xref ref-type="bibr" rid="bib19">Dabertrand et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Rosehart et al., 2021</xref>). Overall, these observations suggest that COX-2 pyramidal cells can sequentially promote both vasodilation and vasoconstriction through the release of PGE2, depending on the context.</p><p>Consistent with previous reports in rodents (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib99">Yamagata et al., 1993</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>), the transcripts of the rate-limiting enzymes COX-1 and COX-2, were detected in subpopulations of mouse layer II-III pyramidal cells, respectively. COX-1/2 expression was found to be systematically associated with at least one PGE2 synthesizing enzyme. The major isoforms were cPGES and mPGES2, with the latter being less prevalent (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>). The low detection rate of mPGES1, an isoform co-induced with COX-2 by various stimuli (<xref ref-type="bibr" rid="bib87">Takemiya et al., 2007</xref>; <xref ref-type="bibr" rid="bib100">Yamagata et al., 2001</xref>), reflects its low constitutive basal expression level. The presence of PM-PGFS, CBR1 and AKR1B3 in layer II-III pyramidal cells is consistent with single-cell RNAseq data (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>). The expression of a PGFS was systematically observed in COX-2 positive pyramidal cells and in a majority of COX-1 positive neurons, similar to PGES. These observations collectively indicate that subpopulations of layer II-III pyramidal cells express the mRNAs required for PGE2 and PGF2α synthesis derived from COX-1 or COX-2 activity. Our pharmacological observations did not reveal a contribution of PGF2α in neurogenic vasoconstriction, despite the potential ability of pyramidal cells to produce it. This is likely because PGF2αis only detectable in pyramidal neurons under conditions where COX-2 is over-expressed (<xref ref-type="bibr" rid="bib86">Takei et al., 2012</xref>).</p><p>Pyramidal cells may have an indirect effect on vascular activity through the activation of intermediate cell types, in addition to the direct vascular effects of PGE2 and glutamate (<xref ref-type="bibr" rid="bib103">Zhang et al., 2024</xref>). Consistent with previous observations, we found that glutamate transmission from pyramidal cells is involved to some extent (<xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). Additionally, we found that the NPY Y1 receptor plays a key role in neurogenic vasoconstriction. It is likely that glutamatergic transmission contributed to NPY release, considering that NPY GABAergic interneurons express a wide range of ionotropic and metabotropic glutamate receptors (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>). Consistently, the Y1 receptor has been shown to be involved in vasoconstriction induced by sensory and optogenetic stimulation of GABAergic interneurons (<xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>). Activation of group I metabotropic receptors in perivascular astrocytes has been shown to promote vasoconstriction via BK channel-dependent K<sup>+</sup> release (<xref ref-type="bibr" rid="bib29">Girouard et al., 2010</xref>) or 20-HETE (<xref ref-type="bibr" rid="bib55">Mulligan and MacVicar, 2004</xref>). However, the neurogenic vasoconstriction was not affected by the blockade of BK channels, which rules out this astrocytic pathway. In contrast, the inhibition of ω-hydroxylase partially reduced neurogenic vasoconstriction, suggesting the involvement of 20-HETE. Additionally, astrocytes may also have contributed to vasoconstriction through the release of PGE2 derived from COX-1 (<xref ref-type="bibr" rid="bib4">Attwell et al., 2016</xref>), as indicated by its mild impairment under SC-560.</p><p>The observation that both EP1 and Y1 antagonists abolished the vasoconstriction suggests that PGE2 and NPY may act in series and/or in a more complex manner involving their neuronal receptors. One possibility is that PGE2 activates NPY interneurons via the EP1 receptor. However, NPY interneurons barely express its transcript (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Zeisel et al., 2015</xref>) and PGE2 constricts arterioles independently of AP firing, suggesting a direct vascular effect of PGE2. Nevertheless, PGE2 may have facilitated NPY release via pre- and postsynaptic EP2-signaling which have been shown to facilitate glutamate release (<xref ref-type="bibr" rid="bib75">Sang et al., 2005</xref>) and to induce neuronal firing (<xref ref-type="bibr" rid="bib18">Clasadonte et al., 2011</xref>), respectively. On the other hand, in addition to smooth muscle cells, Y1 receptors are also enriched in pyramidal neurons (<xref ref-type="bibr" rid="bib83">Smith et al., 2019</xref>), including COX-2 positive ones (<xref ref-type="bibr" rid="bib89">Tasic et al., 2016</xref>), and this receptor has been shown to increase extracellular glutamate in the hippocampus (<xref ref-type="bibr" rid="bib52">Meurs et al., 2012</xref>). By promoting glutamate and possibly PGE2 release, neuronal activation of the Y1 receptor by NPY may also have favored direct (i.e. PGE2) and indirect (i.e. 20-HETE) vasoconstrictive pathways. The combined activation of vascular and neuronal Y1 receptors may explain the complete blockage of optogenetically induced vasoconstriction by its antagonist BIBP3226. In ex vivo relaxed arterioles, where vasoconstriction is favored (<xref ref-type="bibr" rid="bib8">Blanco et al., 2008</xref>), G<sub>q</sub> or G<sub>i</sub> signaling of EP1 or Y1 receptors, respectively, appears sufficient to induce vasoconstriction. In vivo, where blood flow both induces myogenic tone and allows PGE2 clearance, NPY and PGE2 could also synergistically promote vasoconstriction by decreasing and increasing cAMP and Ca<sup>2+</sup> levels, respectively, in smooth muscle cells. PGE2 and NPY may also exert temporally distinct vasoconstrictor effects. Indeed, exogenous application of NPY induces a rapid and transient vasoconstriction that returns to baseline levels after removal (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>), whereas PGE2-induced vasoconstriction is slower and more persistent (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The more transient effect of NPY likely reflects the presence of multiple NPY-degrading enzymes (<xref ref-type="bibr" rid="bib98">Wagner et al., 2015</xref>) and/or the desensitization of the Y1 receptor (<xref ref-type="bibr" rid="bib95">Tsurumaki et al., 2003</xref>; <xref ref-type="bibr" rid="bib28">Gicquiaux et al., 2002</xref>; <xref ref-type="bibr" rid="bib94">Tsurumaki et al., 2002</xref>) which is not the case for PGE2 (<xref ref-type="bibr" rid="bib1">Alix et al., 2008</xref>) and its vasoconstrictor receptors.</p><p>In awake mice, synchronous pyramidal cell activity occurs in the absence of any stimulus during the so-called resting state, but it is observed at a much lower frequency than that which triggers vasoconstriction and is associated with increased blood volume (<xref ref-type="bibr" rid="bib50">Ma et al., 2016</xref>). Therefore, neurogenic vasoconstriction described here is unlikely to occur under these conditions. Brief sensory stimulation increases pyramidal cell activity and largely causes vasodilation in both awake and anesthetized animals (<xref ref-type="bibr" rid="bib71">Rungta et al., 2021</xref>). This hyperemic response can be followed by delayed vasoconstriction (<xref ref-type="bibr" rid="bib22">Devor et al., 2007</xref>) and involves NPY/Y1 receptor signaling (<xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>), similar to the mechanisms reported here. It remains unclear whether PGE2 signaling is also involved in this secondary response. During prolonged sensory stimulation the evoked hyperemic response appears to be more restricted to the activated area at the end of the stimulation than at the beginning (<xref ref-type="bibr" rid="bib6">Berwick et al., 2008</xref>). It is possible that neurogenic vasoconstriction contributes to the later spatial confinement of the vascular response. The time-locked photostimulation of virtually all pyramidal cells leading to vasoconstriction would have resulted in hypersynchrony, a phenomenon that can be observed during sleep/wake transitions (<xref ref-type="bibr" rid="bib2">Asadi-Pooya and Sperling, 2019</xref>). A decrease in hemodynamics has been reported during the transition from rapid eye movement sleep to wakefulness (<xref ref-type="bibr" rid="bib27">Gheres et al., 2023</xref>; <xref ref-type="bibr" rid="bib93">Tsai et al., 2021</xref>), possibly involving neurogenic vasoconstriction. Hypersynchrony is also observed in pathological conditions such as epileptic seizures (<xref ref-type="bibr" rid="bib38">Jiruska et al., 2013</xref>) and in early stages of Alzheimer’s disease (<xref ref-type="bibr" rid="bib7">Bezzina et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Palop et al., 2007</xref>). Although vasoconstriction observed in epilepsy (<xref ref-type="bibr" rid="bib25">Farrell et al., 2016</xref>) exhibits similarities to the neurogenic vasoconstriction described herein, there are notable differences between the two. Like neurogenic vasoconstriction, seizure-induced hypoperfusion is dependent on COX-2 (<xref ref-type="bibr" rid="bib25">Farrell et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Tran et al., 2020</xref>) and, to some extent on PGE2 (<xref ref-type="bibr" rid="bib25">Farrell et al., 2016</xref>), likely through EP1 and/or EP3 receptors. However, epileptic seizures induce the overexpression of both COX-2 and mPGES1 (<xref ref-type="bibr" rid="bib87">Takemiya et al., 2007</xref>; <xref ref-type="bibr" rid="bib99">Yamagata et al., 1993</xref>) as well as the ectopic expression of NPY (<xref ref-type="bibr" rid="bib5">Baraban, 2004</xref>). Similar transcriptional upregulations have also been reported in Alzheimer’s disease (<xref ref-type="bibr" rid="bib7">Bezzina et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Chaudhry et al., 2008</xref>; <xref ref-type="bibr" rid="bib59">Palop et al., 2007</xref>; <xref ref-type="bibr" rid="bib61">Pasinetti and Aisen, 1998</xref>) Additionally, PGF2α synthesis by COX-2 pyramidal cells is also observed during seizures (<xref ref-type="bibr" rid="bib86">Takei et al., 2012</xref>). Taken together, these observations suggest that the mechanisms governing neurogenic vasoconstriction are exacerbated in pathological hypersynchrony and may represent potential therapeutic targets.</p><p>This neurogenic vasoconstriction, observed during strong pyramidal cell activity, may seem counterintuitive as it would lead to an undersupply of energy substrates despite a high energy demand. However, vasoconstriction has been reported contralateral to the main activated area, despite bilateral increases in neuronal activity and blood glucose uptake (<xref ref-type="bibr" rid="bib23">Devor et al., 2008</xref>), suggesting that neurogenic vasoconstriction plays a physiological role. Through glutamate uptake by astrocytes, neuronal activity stimulates blood glucose uptake and lactate release (<xref ref-type="bibr" rid="bib62">Pellerin and Magistretti, 1994</xref>; <xref ref-type="bibr" rid="bib97">Voutsinos-Porche et al., 2003</xref>). In addition to its role as an oxidative energy substrate for cortical neurons, lactate is also a signaling molecule that enhances their spiking activity (<xref ref-type="bibr" rid="bib42">Karagiannis et al., 2021</xref>). Therefore, uncontrolled lactate supply and metabolism could potentially lead to deleterious hyperactivity (<xref ref-type="bibr" rid="bib14">Cauli et al., 2023</xref>; <xref ref-type="bibr" rid="bib72">Sada et al., 2015</xref>). Thus, the purpose of neurogenic vasoconstriction may be to restrict energy delivery to prevent an overexcitation of the cortical network.</p><p>Here, using multidisciplinary approaches, we describe a new mechanism of vasoconstriction that depends on a high firing rate of pyramidal cells. This neurogenic vasoconstriction primarily involves the release of COX-2-derived PGE2 and activation of EP1 and EP3 receptors. It is mediated by direct effects on vascular smooth muscle cells but also by indirect mechanisms involving NPY release from GABAergic interneurons and astrocytes by 20-HETE synthesis. In contrast to previously described mechanisms of neurogenic vasoconstriction, that have been mostly associated with GABAergic interneurons and neuronal inhibition (<xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>; <xref ref-type="bibr" rid="bib22">Devor et al., 2007</xref>; <xref ref-type="bibr" rid="bib44">Krawchuk et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib96">Uhlirova et al., 2016</xref>), our data suggest the involvement of glutamatergic excitatory neurons and increased neuronal activity. This finding will help to update the interpretation of the functional brain imaging signals used to map network activity in health and disease (<xref ref-type="bibr" rid="bib37">Iadecola, 2017</xref>; <xref ref-type="bibr" rid="bib102">Zhang and Raichle, 2010</xref>). This excitatory form of neurogenic vasoconstriction may also help to understand the etiopathogenesis of epilepsy (<xref ref-type="bibr" rid="bib25">Farrell et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Tran et al., 2020</xref>) and Alzheimer’s disease (<xref ref-type="bibr" rid="bib60">Palop and Mucke, 2010</xref>) in which increased cortical network activity and hypoperfusion often overlap.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>Homozygous Emx1-Cre mice Jackson Laboratory, stock #005628, B6.129S2-Emx1<italic><sup>tm1(cre)Krj</sup></italic>/J (<xref ref-type="bibr" rid="bib31">Gorski et al., 2002</xref>) were crossed with homozygous Ai32 mice [Jackson Laboratory, stock #012569, B6;129S-Gt(ROSA)26Sor<sup>tm32(CAG-COP4*H134R/EYFP)Hze</sup>/J (<xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>)] to obtain heterozygous Emx1<sup>cre/WT</sup>;Ai32<sup>ChR2/WT</sup> mice for optogenetic stimulations. C57BL/6RJ mice were used for PGE2 and sulprostone exogenous applications, control optogenetic experiments and single-cell RT-PCR. 16–21 postnatal day-old females and males were used for all ex vivo experiments. Female Emx1<sup>cre/WT</sup>;Ai32<sup>ChR2/WT</sup> mice, 3- to 5-month-old, were used for in vivo experiments.</p><p>All experimental procedures using animals were carried out in strict accordance with French regulations (Code Rural R214/87 to R214/130) and conformed to the ethical guidelines of the European Communities Council Directive of September 22, 2010 (2010/63/UE). Mice were fed ad libitum and housed in a 12 hr light/dark cycle. In vivo experiments were done in accordance with the Institut national de la santé et de la recherche médicale (Inserm) animal care and approved by the ethical committee Charles Darwin (Comité national de réflexion éthique sur l’expérimentation animale – n°5) (protocol number #27135 2020091012114621).</p></sec><sec id="s4-2"><title>Ex vivo slice preparation</title><p>Mice were deeply anesthetized by isoflurane (IsoVet, Piramal Healthcare UK or IsoFlo, Axience) evaporation in an induction box then euthanized by decapitation. The brain was quickly removed and placed in cold (~4 °C), oxygenated artificial cerebrospinal fluid (aCSF) containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 10 glucose, 15 sucrose and 1 kynurenic acid (Sigma-Aldrich). 300-µm-thick coronal slices containing the barrel cortex were cut with a vibratome (VT1000s; Leica) and were allowed to recover at room temperature for at least 45 min with oxygenated aCSF (95% O2/5% CO2; <xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref>). The slices were then transferred to a submerged recording chamber and perfused continuously at room temperature (20–25°C) at a rate of 2 ml/min with oxygenated aCSF lacking kynurenic acid.</p></sec><sec id="s4-3"><title>Whole-cell recordings</title><p>Patch pipettes (5.5±0.2 MΩ) pulled from borosilicate glass were filled with 8 µl of RNase free internal solution containing (in mM): 144 K-gluconate, 3 MgCl2, 0.5 EGTA, 10 HEPES, pH 7.2 (285/295 mOsm). For electrophysiological recordings combined with calcium imaging, EGTA was replaced by 200 µM Rhod-2 (20777, Cayman chemicals). Whole-cell recordings were performed using a patch-clamp amplifier (Axopatch 200B, MDS). Data were filtered at 5–10 kHz and digitized at 50 kHz using an acquisition board (Digidata 1440, MDS) attached to a personal computer running pCLAMP 10.2 software package (MDS). Electrophysiological properties were determined in current-clamp mode (<xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref>). Membrane potential values were corrected for theoretical liquid junction potential (−15.6 mV). Resting membrane potential of neurons was measured immediately after passing in whole-cell configuration. Only neurons with a resting membrane potential more hyperpolarized than −60 mV were analyzed further.</p></sec><sec id="s4-4"><title>Optogenetic stimulation</title><p>Optogenetic stimulation was achieved through the objective using a 470 nm light emitting device (LED, CoolLED, Precise Excite) attached to the epifluorescence port of a BX51WI microscope (Olympus) and a set of multiband filters consisting of an excitation filter (HC 392/474/554/635, Semrock), a dichroic mirror (BS 409/493/573/652, Semrock), and an emission filter (HC 432/515/595/730, Semrock). Photostimulation consisted of a 10 s train of 5ms light pulses at an intensity of 38 mW/mm² and delivered at five different frequencies (1, 2, 5, 10, and 20 Hz).</p></sec><sec id="s4-5"><title>Infrared imaging</title><p>Blood vessels and cells were observed in slices under infrared illumination with Dodt gradient contrast optics (IR-DGC, Luigs and Neumann) using a double-port upright microscope (BX51WI, Olympus) and a collimated light emitting device (LED; 780 nm; ThorLabs) as the transmitted light source, a 40 X (LUMPlanF/IR, 40 X/0.80 W, Olympus) or a 60 X (LUMPlan FL/IR 60 X/0.90 W, Olympus) objective and a digital camera (OrcaFlash 4.0, Hamamatsu) attached to the front port of the microscope. Penetrating arterioles in layer I were selected by IR-DGC videomicroscopy based on their well-defined luminal diameter (10–40 µm), their length remaining in the focal plane for at least 50 µm (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>), and the thickness of their wall (4.1±0.1 µm, n=176 blood vessels). A resting period of at least 30 min (<xref ref-type="bibr" rid="bib105">Zonta et al., 2003</xref>) was observed after slice transfer. After light-induced responses, arteriolar contractility was tested by the application of aCSF containing the thromboxane A2 agonist, U46619 (100 nM; <xref ref-type="bibr" rid="bib12">Cauli et al., 2004</xref>) or K<sup>+</sup> enriched solution (composition in mM: 77.5 NaCl, 50 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 10 glucose, 15 sucrose). Vessels that did not constrict with these applications were discarded. Only one arteriole was monitored per slice receiving a single optogenetic or pharmacological stimulation. IR-DGC images were acquired at 0.1 Hz for pharmacological applications and at 1 Hz for optogenetic experiments using Imaging Workbench 6.1 software(Indec Biosystems). The focal plane was continuously maintained on-line using IR-DGC images of cells as anatomical landmarks (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>).</p></sec><sec id="s4-6"><title>Calcium imaging</title><p>Visually and electrophysiologically identified layer II-III pyramidal cells were filled with the calcium-sensitive dye Rhod-2 (200 µM, Cayman chemical, 20777) using patch pipettes. Optical recordings were made at least 15 min after passing in whole-cell configuration to allow for somatic diffusion of the dye. Rhod-2 was excited with a 585 nm LED (Cool LED, Precise Excite) at an intensity of 0.56 mW/mm² and the filter set used for optogenetic stimulation using the Imaging Workbench 6.1 software(Indec Byosystems). IR-DGC and fluorescence images were acquired by alternating epifluorescence and transmitted light sources. IR-DGC and fluorescence were respectively sampled at 5 Hz and 1 Hz during baseline and optogenetic stimulation, respectively, and at 1 Hz and 0.2 Hz after photostimulation. During photostimulation, bleed-through occurred in the Rhod-2 channel due to the fluorescence of the EYFP-ChR2 transgene (<xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>). Therefore, the Ca<sup>2+</sup> response could not be reliably analyzed during this period. To compensate for potential x-y drifts, all images were registered off-line using the ‘StackReg’ plug-in (<xref ref-type="bibr" rid="bib90">Thévenaz et al., 1998</xref>) of the ImageJ 1.53 software. To define somatic regions of interest (ROIs), the soma was manually delineated from IR-DGC images. Fluorescence intensity changes (ΔF/F<sub>0</sub>) were expressed as the ratio (F-F<sub>0</sub>)/F<sub>0</sub> where F is the mean fluorescence intensity in the ROI at a given time point, and F<sub>0</sub> is the mean fluorescence intensity in the same ROI during the 30 s control baseline.</p></sec><sec id="s4-7"><title>Drugs</title><p>All pharmacological compounds were bath applied after a 5-min baseline, and vascular dynamics were recorded during bath application. The following drugs were dissolved in water: D-(-)–2-amino-5-phosphonopentanoic acid (D-AP5, 50 µM, Hello Bio, HB0225), 6,7-dinitroquinoxaline-2,3-dione (DNQX, 10 µM, Hello Bio, HB0262), LY367385 (100 µM, Hello Bio, HB0398) and BIBP3226 (1 µM, Tocris, 2707). Tetrodotoxin (TTX, 1 µM, L8503, Latoxan) was dissolved in 90% acetic acid. PGE2 (HB3460, Hello Bio), sulprostone (10 µM, Cayman chemical, 14765), 2-methyl-6-(phenylethynyl)pyridine (MPEP, 50 µM, Hello Bio, HB0426) and 9,11-dideoxy-9α,11α-methanoepoxy prostaglandin F2α (U-46619, 100 nM, Enzo, BML-PG023) were dissolved in ethanol. Indomethacin (5 µM, Sigma-Aldrich, I7378), SC-560 (100 nM, Sigma-Aldrich, S2064-5MG), NS-398 (10 µM, Enzo, BML-EI261), ONO-8130 (10 nM, Tocris, 5406), L-798,106 (1 µM, Cayman chemical, 11129), AL8810 (10 µM, Cayman chemical, 16735), paxilline (10 µM, Tocris, 2006) and HET0016 (100 µM, Merck, SML2416-5MG) in DMSO. Acetic acid, ethanol and DMSO doses were always used below 0.1%. Synthesis inhibitors and BIBP3226 were applied at least 30 min before optogenetic stimulation. TTX was applied at least 15 min before, while glutamate receptor antagonists and paxilline were applied at least 10 and 5 min before, respectively.</p></sec><sec id="s4-8"><title>Vascular reactivity analysis</title><p>To compensate for potential x-y drifts, all images were realigned off-line using the ‘StackReg’ plug-in <xref ref-type="bibr" rid="bib90">Thévenaz et al., 1998</xref> of the ImageJ 1.53 software. Luminal diameter was measured in layer I on registered images using custom analysis software developed in MATLAB (MathWorks) (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>). To avoid potential drawbacks due to vessel instability, only arterioles with a stable diameter were analyzed further. Arterioles were considered stable if the relative standard deviation of their diameter during the baseline period was less than 5% (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>). Comparison of the mean arteriolar diameter during the 5 min baseline and the 5 min final pharmacological treatments revealed that all drugs, except AL8810, had no effect on resting diameter (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>Diameter changes (ΔD/D<sub>0</sub>) were expressed as (D<sub>t</sub> – D<sub>0</sub>)/D<sub>0</sub> where D<sub>t</sub> is the diameter at the time t and D<sub>0</sub> is the mean diameter during the baseline period. To eliminate sharp artifacts due to transient loss of focus, diameter change traces were smoothed using a sliding three-point median filter. The overall vascular response over time was captured by the area under the curve of diameter changes after photostimulation. To determine the onset of vasoconstriction, a Z-score was calculated from the diameter change traces using the formula: Z = (x - μ)/ σ, where both the mean μ and the standard deviation σ were calculated from the values before photostimulation. Onset of vasoconstriction was defined as the time after the start of photostimulation at which the Z-score exceeded or fell below -a value of –1.96 (95% criteria) for 10 s. If a vessel showed no vasoconstriction, the onset was arbitrarily set at 1800s. Graphs were generated using R software version 4.3.0 (<xref ref-type="bibr" rid="bib66">R Development Core Team, 2023</xref>) and Matplotlib package (<xref ref-type="bibr" rid="bib11">Caswell, 2023</xref>).</p></sec><sec id="s4-9"><title>Intrinsic optical signals analysis</title><p>Variations in IR light transmittance (ΔT) (<xref ref-type="bibr" rid="bib104">Zhou et al., 2010</xref>) were determined using ImageJ 1.53 software according to: ΔT = (T<sub>t</sub> -T<sub>0</sub>)/ T<sub>0</sub> where T<sub>t</sub> is the light transmittance at a time t and T0 is the average light transmittance during the baseline period of a squared region of interest of 100 µm x 100 µm manually delineated in layer I. The rate of ΔT change was determined as the first derivative of ΔT (dΔT/dt, where ΔT is the change in light transmittance and t is time). Slices that showed a maximum rate of increase of dΔT/dt greater than 2% /s, indicating the occurrence of spreading depression (<xref ref-type="bibr" rid="bib104">Zhou et al., 2010</xref>), were excluded.</p></sec><sec id="s4-10"><title>Surgery</title><p>Chronic cranial windows were implanted one week after the head bar surgery as previously described (<xref ref-type="bibr" rid="bib91">Tournissac et al., 2022</xref>). We used a 100 μm thick glass coverslip over the barrel cortex (~4 mm<sup>2</sup>). Before two-photon experiments, a recovery period of 7–10 days minimum was respected.</p></sec><sec id="s4-11"><title>In vivo two-photon imaging and photostimulation</title><p>For two-photon excitation, we used a femtosecond laser (Mai Tai eHP; SpectraPhysics) with a dispersion compensation module (Deepsee; SpectraPhysics) emitting 70-fs pulses at 80 MHz. The laser power was attenuated by an acousto-optical modulator (AA Optoelectronic, MT110-B50-A1.5-IR-Hk). Scanning was performed with Galvanometric scanner (GS) mirrors (8315KM60B; Cambridge Technology). Fluorescein was excited at 920 nm and the emitted light was collected with a LUMFLN60XW (Olympus, 1.1 NA) water immersion objective. Collected photons were sorted using a dichroic mirror centered at 570 nm, a FF01-525/50 nm filter (Semrock) and a GaAsP (Hamamatsu) photomultipliers tube. Customized LabView software was used to control the system. Line-scans were drawn across pial vessels to measure the change in arterioles diameter, which are not compromised by the fluorescence from the ChR2-EYFP transgene in the parenchyma (<xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref>), are less affected by potential movement in the x-y plan than in penetrating arterioles, and whose dilation dynamics are similar in the somatosensory cortex (<xref ref-type="bibr" rid="bib71">Rungta et al., 2021</xref>).</p><p>Mice were anesthetized with a mixture of ketamine and medetomidine (100 and 0.5 mg/kg, respectively, intraperitoneally (i.p.)) during imaging sessions. Body temperature was maintained at 36.5°C with a retro-controlled heating pad. Fluorescein dextran (70 kDa) was injected i.v. through a retro-orbital injection to label brain vessels. Mice received continuous air through a nose cone supplemented with oxygen to reach a final concentration of 30% O<sub>2</sub>.</p><p>Photostimulation was delivered with a 473 nm laser (Coblot MLD, Sweden) through an optical fiber placed above the glass coverslip and directed at the pial artery of interest. Each photostimulation consisted of a 10-second train of 5 ms light pulses at an intensity of 1 mW delivered at 10 Hz, with a 5-minute interstimulus interval to allow full recovery to baseline. Indomethacin (10 mg/kg, #15425529, Thermo Fisher Scientific) was administered i.v. through a retro-orbital injection.</p></sec><sec id="s4-12"><title>Imaging analysis</title><p>Pial arteriole diameter change was determined with line-scan acquisitions and a home-made Matlab script as previously described (<xref ref-type="bibr" rid="bib70">Rungta et al., 2018</xref>). Trials from the same vessel were averaged (with a 0.1 s interpolation) for analysis. Area under the curve and statistics were performed using GraphPad Prim (version 6).</p></sec><sec id="s4-13"><title>Cytoplasm harvesting and single-cell RT-PCR</title><p>At the end of the whole-cell recording, which lasted less than 15 min, the cytoplasmic content was collected in the recording pipette by applying a gentle negative pressure. The pipette’s content was expelled into a test tube and RT was performed in a final volume of 10 µl as described previously (<xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref>). The scRT-PCR protocol was designed to probed simultaneously the expression of prostaglandins synthesizing enzymes and neuronal markers (<xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>). Prostaglandins synthesizing enzymes included COX-1 and COX-2, the terminal PGE2 synthases (PGES): mPGES1, mPGES2 and cPGES, the terminal PGF2αsynthases (PGFS): PM-PGFS (Prxl2b) and AKR1B3 and the carbonyl reductase CBR1. Neuronal markers included the vesicular glutamate transporter, vGluT1, and the two isoforms of glutamic acid decarboxylase, GAD65 and GAD67. Two-step amplification was performed essentially as described (<xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref>). First, cDNAs present in the 10 µl reverse transcription reaction were simultaneously amplified with all external primer pairs listed in Appendix 1—key resources table. Taq polymerase (2.5 U; QIAGEN) and external primers mix (20 pmol each) were added to the manufacturer’s buffer (final volume, 100 µl), and 20 cycles (95◦C, 30 s; 60◦C, 30 s; and 72◦C, 35 s) of PCR were performed. Second rounds of PCR were performed using 1 µl of the first PCR product as a template. In this second round, each cDNA was amplified individually using its specific nested primer pair (Appendix 1—key resources table) by performing 35 PCR cycles (as described above). 10 µl of each individual PCR product were run on a 2% agarose gel stained with ethidium bromide using ΦX174 digested by <italic>HaeIII</italic> as a molecular weight marker. The efficiency of the protocol was validated using 500 pg of total forebrain RNAs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p></sec><sec id="s4-14"><title>Statistical analyses</title><p>Statistical analyses were performed using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California USA, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>) and R software version 4.3.0 (<xref ref-type="bibr" rid="bib66">R Development Core Team, 2023</xref>). Normality of distribution was assessed using the Shapiro-Wilk tests. Equality of variance was assessed using Brown-Forsythe tests for comparisons between groups and using F-tests for comparisons with a control group. Parametric tests were only used if these criteria were met. Statistical significance of morphological and physiological properties of penetrating arterioles was determined using one-way ANOVA for comparison between groups. Statistical significance of calcium was determined using two-tailed unpaired t-tests and Statistical significance of vascular responses were appreciated using Tukey posthoc tests for the different frequencies conditions and using Dunnett’s posthoc tests for the different pharmacological conditions compared to the 20 Hz condition without pharmacological compound. False discovery rate correction was used for multiple comparisons. Statistical significance of vascular diameter for drug applications was determined using two-tailed paired t-tests. Statistical significance on all figures uses the following convention: *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experimental procedures using animals were carried out in strict accordance with French regulations (Code Rural R214/87 to R214/130) and conformed to the ethical guidelines of the European Communities Council Directive of September 22, 2010 (2010/63/UE). Mice were fed ad libitum and housed in a 12-hour light/dark cycle. In vivo experiments were done in accordance with the Institut national de la santé et de la recherche médicale (Inserm) animal care and approved by the ethical committee Charles Darwin (Comité national de réflexion éthique sur l'expérimentation animale - n°5) (protocol number #27135 2020091012114621).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102424-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Matlab script for blood vessel analysis.</title><p>The method has been described in <xref ref-type="bibr" rid="bib45">Lacroix et al., 2015</xref>.</p></caption><media xlink:href="elife-102424-code1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1 to 6. Source code for blood vessel analysis is provided in <xref ref-type="supplementary-material" rid="scode1">Source code 1</xref>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Dr Rebecca Piskorowski for constructive criticism of the manuscript. We acknowledge the invaluable support of the animal facilities of IBPS (RongIBPS) and Institut de la vision for their expert care and maintenance of the animals used in this study. Financial support was provided by grants from the Agence Nationale pour la Recherche (ANR-17-CE37-0010-03, BC; CE37_2020_TF-fUS-CADASIL, SC; ANR-20-CE14-0025, DL; ANR-23-CE14-0038-01, BC), the Fondation Alzheimer France (M21JRCN009, SC) and the i-Bio initiative of Sorbonne University (BC). BLG and EB were supported by fellowships from Fondation pour la Recherche sur Alzheimer and MT by a fellowship from the Fondation pour la Recherche Médicale (SPF201909009103)</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alix</surname><given-names>E</given-names></name><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Strazielle</surname><given-names>N</given-names></name><name><surname>Ghersi-Egea</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prostaglandin E2 metabolism in rat brain: role of the blood-brain interfaces</article-title><source>Cerebrospinal Fluid Research</source><volume>5</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/1743-8454-5-5</pub-id><pub-id pub-id-type="pmid">18318891</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asadi-Pooya</surname><given-names>AA</given-names></name><name><surname>Sperling</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Normal awake, drowsy, and sleep EEG patterns that might be overinterpreted as abnormal</article-title><source>Journal of Clinical Neurophysiology</source><volume>36</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1097/WNP.0000000000000585</pub-id><pub-id pub-id-type="pmid">31274687</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attwell</surname><given-names>D</given-names></name><name><surname>Buchan</surname><given-names>AM</given-names></name><name><surname>Charpak</surname><given-names>S</given-names></name><name><surname>Lauritzen</surname><given-names>M</given-names></name><name><surname>Macvicar</surname><given-names>BA</given-names></name><name><surname>Newman</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Glial and neuronal control of brain blood flow</article-title><source>Nature</source><volume>468</volume><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/nature09613</pub-id><pub-id pub-id-type="pmid">21068832</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attwell</surname><given-names>D</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>CN</given-names></name><name><surname>O’Farrell</surname><given-names>FM</given-names></name><name><surname>Dalkara</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>What is a pericyte?</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>36</volume><fpage>451</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1177/0271678X15610340</pub-id><pub-id pub-id-type="pmid">26661200</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baraban</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Neuropeptide Y and epilepsy: recent progress, prospects and controversies</article-title><source>Neuropeptides</source><volume>38</volume><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.npep.2004.04.006</pub-id><pub-id pub-id-type="pmid">15337378</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berwick</surname><given-names>J</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Martindale</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Kennerley</surname><given-names>AJ</given-names></name><name><surname>Redgrave</surname><given-names>P</given-names></name><name><surname>Mayhew</surname><given-names>JEW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fine detail of neurovascular coupling revealed by spatiotemporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex</article-title><source>Journal of Neurophysiology</source><volume>99</volume><fpage>787</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1152/jn.00658.2007</pub-id><pub-id pub-id-type="pmid">18046008</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezzina</surname><given-names>C</given-names></name><name><surname>Verret</surname><given-names>L</given-names></name><name><surname>Juan</surname><given-names>C</given-names></name><name><surname>Remaud</surname><given-names>J</given-names></name><name><surname>Halley</surname><given-names>H</given-names></name><name><surname>Rampon</surname><given-names>C</given-names></name><name><surname>Dahan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer’s disease</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0119910</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0119910</pub-id><pub-id pub-id-type="pmid">25768013</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>VM</given-names></name><name><surname>Stern</surname><given-names>JE</given-names></name><name><surname>Filosa</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tone-dependent vascular responses to astrocyte-derived signals</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>294</volume><fpage>H2855</fpage><lpage>H2863</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.91451.2007</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boie</surname><given-names>Y</given-names></name><name><surname>Stocco</surname><given-names>R</given-names></name><name><surname>Sawyer</surname><given-names>N</given-names></name><name><surname>Slipetz</surname><given-names>DM</given-names></name><name><surname>Ungrin</surname><given-names>MD</given-names></name><name><surname>Neuschäfer-Rube</surname><given-names>F</given-names></name><name><surname>Püschel</surname><given-names>GP</given-names></name><name><surname>Metters</surname><given-names>KM</given-names></name><name><surname>Abramovitz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes</article-title><source>European Journal of Pharmacology</source><volume>340</volume><fpage>227</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/s0014-2999(97)01383-6</pub-id><pub-id pub-id-type="pmid">9537820</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas</surname><given-names>C</given-names></name><name><surname>Irinopoulou</surname><given-names>T</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Poncer</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular and functional characterization of GAD67-expressing, newborn granule cells in mouse dentate gyrus</article-title><source>Frontiers in Neural Circuits</source><volume>7</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2013.00060</pub-id><pub-id pub-id-type="pmid">23565079</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Caswell</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Matplotlib/matplotlib: REL: v3.7.2</data-title><version designator="v3.7.2">v3.7.2</version><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.8118151">https://doi.org/10.5281/zenodo.8118151</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Tong</surname><given-names>XK</given-names></name><name><surname>Rancillac</surname><given-names>A</given-names></name><name><surname>Serluca</surname><given-names>N</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways</article-title><source>The Journal of Neuroscience</source><volume>24</volume><fpage>8940</fpage><lpage>8949</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3065-04.2004</pub-id><pub-id pub-id-type="pmid">15483113</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Revisiting the role of neurons in neurovascular coupling</article-title><source>Frontiers in Neuroenergetics</source><volume>2</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3389/fnene.2010.00009</pub-id><pub-id pub-id-type="pmid">20616884</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Dusart</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Lactate as a determinant of neuronal excitability, neuroenergetics and beyond</article-title><source>Neurobiology of Disease</source><volume>184</volume><elocation-id>106207</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2023.106207</pub-id><pub-id pub-id-type="pmid">37331530</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>UA</given-names></name><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Doré</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Elevated microsomal prostaglandin-E synthase-1 in Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>4</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2007.10.015</pub-id><pub-id pub-id-type="pmid">18631945</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>E</given-names></name><name><surname>Kagota</surname><given-names>S</given-names></name><name><surname>Wijekoon</surname><given-names>EP</given-names></name><name><surname>McGuire</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice</article-title><source>BMC Pharmacology</source><volume>11</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2210-11-10</pub-id><pub-id pub-id-type="pmid">21955547</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>DY</given-names></name><name><surname>Sadeghian</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>T</given-names></name><name><surname>Lule</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Karakaya</surname><given-names>F</given-names></name><name><surname>Goins</surname><given-names>S</given-names></name><name><surname>Oka</surname><given-names>F</given-names></name><name><surname>Yaseen</surname><given-names>MA</given-names></name><name><surname>Houben</surname><given-names>T</given-names></name><name><surname>Tolner</surname><given-names>EA</given-names></name><name><surname>van den Maagdenberg</surname><given-names>AMJM</given-names></name><name><surname>Whalen</surname><given-names>MJ</given-names></name><name><surname>Sakadžic</surname><given-names>S</given-names></name><name><surname>Ayata</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Determinants of optogenetic cortical spreading depolarizations</article-title><source>Cerebral Cortex</source><volume>29</volume><fpage>1150</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhy021</pub-id><pub-id pub-id-type="pmid">29425263</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clasadonte</surname><given-names>J</given-names></name><name><surname>Poulain</surname><given-names>P</given-names></name><name><surname>Hanchate</surname><given-names>NK</given-names></name><name><surname>Corfas</surname><given-names>G</given-names></name><name><surname>Ojeda</surname><given-names>SR</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prostaglandin E <sub>2</sub> release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation</article-title><source>PNAS</source><volume>108</volume><fpage>16104</fpage><lpage>16109</lpage><pub-id pub-id-type="doi">10.1073/pnas.1107533108</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabertrand</surname><given-names>F</given-names></name><name><surname>Hannah</surname><given-names>RM</given-names></name><name><surname>Pearson</surname><given-names>JM</given-names></name><name><surname>Hill-Eubanks</surname><given-names>DC</given-names></name><name><surname>Brayden</surname><given-names>JE</given-names></name><name><surname>Nelson</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prostaglandin E2, a postulated astrocyte-derived neurovascular coupling agent, constricts rather than dilates parenchymal arterioles</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>33</volume><fpage>479</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2013.9</pub-id><pub-id pub-id-type="pmid">23385200</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>April</surname><given-names>H</given-names></name><name><surname>Nwaneshiudu</surname><given-names>C</given-names></name><name><surname>Ashby</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration</article-title><source>Molecular Pharmacology</source><volume>58</volume><fpage>1279</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1124/mol.58.6.1279</pub-id><pub-id pub-id-type="pmid">11093764</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devienne</surname><given-names>G</given-names></name><name><surname>Le Gac</surname><given-names>B</given-names></name><name><surname>Piquet</surname><given-names>J</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single cell multiplex reverse transcription polymerase chain reaction after patch-clamp</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>57627</elocation-id><pub-id pub-id-type="doi">10.3791/57627</pub-id><pub-id pub-id-type="pmid">29985318</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devor</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>P</given-names></name><name><surname>Nishimura</surname><given-names>N</given-names></name><name><surname>Teng</surname><given-names>IC</given-names></name><name><surname>Hillman</surname><given-names>EMC</given-names></name><name><surname>Narayanan</surname><given-names>SN</given-names></name><name><surname>Ulbert</surname><given-names>I</given-names></name><name><surname>Boas</surname><given-names>DA</given-names></name><name><surname>Kleinfeld</surname><given-names>D</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>4452</fpage><lpage>4459</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0134-07.2007</pub-id><pub-id pub-id-type="pmid">17442830</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devor</surname><given-names>A</given-names></name><name><surname>Hillman</surname><given-names>EMC</given-names></name><name><surname>Tian</surname><given-names>P</given-names></name><name><surname>Waeber</surname><given-names>C</given-names></name><name><surname>Teng</surname><given-names>IC</given-names></name><name><surname>Ruvinskaya</surname><given-names>L</given-names></name><name><surname>Shalinsky</surname><given-names>MH</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Haslinger</surname><given-names>RH</given-names></name><name><surname>Narayanan</surname><given-names>SN</given-names></name><name><surname>Ulbert</surname><given-names>I</given-names></name><name><surname>Dunn</surname><given-names>AK</given-names></name><name><surname>Lo</surname><given-names>EH</given-names></name><name><surname>Rosen</surname><given-names>BR</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Kleinfeld</surname><given-names>D</given-names></name><name><surname>Boas</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Stimulus-induced changes in blood flow and 2-deoxyglucose uptake dissociate in ipsilateral somatosensory cortex</article-title><source>The Journal of Neuroscience</source><volume>28</volume><fpage>14347</fpage><lpage>14357</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4307-08.2008</pub-id><pub-id pub-id-type="pmid">19118167</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Cesare</surname><given-names>A</given-names></name><name><surname>Del Piccolo</surname><given-names>P</given-names></name><name><surname>Zacchetti</surname><given-names>D</given-names></name><name><surname>Grohovaz</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>EP2 receptor stimulation promotes calcium responses in astrocytes via activation of the adenylyl cyclase pathway</article-title><source>Cellular and Molecular Life Sciences</source><volume>63</volume><fpage>2546</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1007/s00018-006-6262-9</pub-id><pub-id pub-id-type="pmid">17058034</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>JS</given-names></name><name><surname>Gaxiola-Valdez</surname><given-names>I</given-names></name><name><surname>Wolff</surname><given-names>MD</given-names></name><name><surname>David</surname><given-names>LS</given-names></name><name><surname>Dika</surname><given-names>HI</given-names></name><name><surname>Geeraert</surname><given-names>BL</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Spanswick</surname><given-names>SC</given-names></name><name><surname>Dunn</surname><given-names>JF</given-names></name><name><surname>Antle</surname><given-names>MC</given-names></name><name><surname>Federico</surname><given-names>P</given-names></name><name><surname>Campbell Teskey</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Postictal behavioural impairments are due to a severe prolonged hypoperfusion/ hypoxia event that is COX-2 dependent</article-title><source>eLife</source><volume>1</volume><elocation-id>e2001</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.19352.001</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Férézou</surname><given-names>I</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Hill</surname><given-names>EL</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>5-HT3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>7389</fpage><lpage>7397</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-17-07389.2002</pub-id><pub-id pub-id-type="pmid">12196560</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheres</surname><given-names>KW</given-names></name><name><surname>Ünsal</surname><given-names>HS</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Turner</surname><given-names>KL</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Drew</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Arousal state transitions occlude sensory-evoked neurovascular coupling in neonatal mice</article-title><source>Communications Biology</source><volume>6</volume><elocation-id>738</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-023-05121-5</pub-id><pub-id pub-id-type="pmid">37460780</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gicquiaux</surname><given-names>H</given-names></name><name><surname>Lecat</surname><given-names>S</given-names></name><name><surname>Gaire</surname><given-names>M</given-names></name><name><surname>Dieterlen</surname><given-names>A</given-names></name><name><surname>Mély</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Bucher</surname><given-names>B</given-names></name><name><surname>Galzi</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>6645</fpage><lpage>6655</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107224200</pub-id><pub-id pub-id-type="pmid">11741903</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girouard</surname><given-names>H</given-names></name><name><surname>Bonev</surname><given-names>AD</given-names></name><name><surname>Hannah</surname><given-names>RM</given-names></name><name><surname>Meredith</surname><given-names>A</given-names></name><name><surname>Aldrich</surname><given-names>RW</given-names></name><name><surname>Nelson</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Astrocytic endfoot Ca2+ and BK channels determine both arteriolar dilation and constriction</article-title><source>PNAS</source><volume>107</volume><fpage>3811</fpage><lpage>3816</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914722107</pub-id><pub-id pub-id-type="pmid">20133576</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>GRJ</given-names></name><name><surname>Choi</surname><given-names>HB</given-names></name><name><surname>Rungta</surname><given-names>RL</given-names></name><name><surname>Ellis-Davies</surname><given-names>GCR</given-names></name><name><surname>MacVicar</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Brain metabolism dictates the polarity of astrocyte control over arterioles</article-title><source>Nature</source><volume>456</volume><fpage>745</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/nature07525</pub-id><pub-id pub-id-type="pmid">18971930</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname><given-names>JA</given-names></name><name><surname>Talley</surname><given-names>T</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Puelles</surname><given-names>L</given-names></name><name><surname>Rubenstein</surname><given-names>JLR</given-names></name><name><surname>Jones</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>6309</fpage><lpage>6314</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-15-06309.2002</pub-id><pub-id pub-id-type="pmid">12151506</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>BW</given-names></name><name><surname>Klimko</surname><given-names>P</given-names></name><name><surname>Crider</surname><given-names>JY</given-names></name><name><surname>Sharif</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>290</volume><fpage>1278</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">10454504</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grutzendler</surname><given-names>J</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cellular control of brain capillary blood flow: in vivo imaging veritas</article-title><source>Trends in Neurosciences</source><volume>42</volume><fpage>528</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2019.05.009</pub-id><pub-id pub-id-type="pmid">31255380</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>DA</given-names></name><name><surname>Berthiaume</surname><given-names>A-A</given-names></name><name><surname>Grant</surname><given-names>RI</given-names></name><name><surname>Harrill</surname><given-names>SA</given-names></name><name><surname>Koski</surname><given-names>T</given-names></name><name><surname>Tieu</surname><given-names>T</given-names></name><name><surname>McDowell</surname><given-names>KP</given-names></name><name><surname>Faino</surname><given-names>AV</given-names></name><name><surname>Kelly</surname><given-names>AL</given-names></name><name><surname>Shih</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Brain capillary pericytes exert a substantial but slow influence on blood flow</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>633</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-00793-2</pub-id><pub-id pub-id-type="pmid">33603231</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>RA</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Murikinati</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Grutzendler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes</article-title><source>Neuron</source><volume>87</volume><fpage>95</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.06.001</pub-id><pub-id pub-id-type="pmid">26119027</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Glial regulation of the cerebral microvasculature</article-title><source>Nature Neuroscience</source><volume>10</volume><fpage>1369</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1038/nn2003</pub-id><pub-id pub-id-type="pmid">17965657</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease</article-title><source>Neuron</source><volume>96</volume><fpage>17</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.030</pub-id><pub-id pub-id-type="pmid">28957666</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiruska</surname><given-names>P</given-names></name><name><surname>de Curtis</surname><given-names>M</given-names></name><name><surname>Jefferys</surname><given-names>JGR</given-names></name><name><surname>Schevon</surname><given-names>CA</given-names></name><name><surname>Schiff</surname><given-names>SJ</given-names></name><name><surname>Schindler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Synchronization and desynchronization in epilepsy: controversies and hypotheses</article-title><source>The Journal of Physiology</source><volume>591</volume><fpage>787</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2012.239590</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juteau</surname><given-names>H</given-names></name><name><surname>Gareau</surname><given-names>Y</given-names></name><name><surname>Labelle</surname><given-names>M</given-names></name><name><surname>Sturino</surname><given-names>CF</given-names></name><name><surname>Sawyer</surname><given-names>N</given-names></name><name><surname>Tremblay</surname><given-names>N</given-names></name><name><surname>Lamontagne</surname><given-names>S</given-names></name><name><surname>Carrière</surname><given-names>MC</given-names></name><name><surname>Denis</surname><given-names>D</given-names></name><name><surname>Metters</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure–activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>9</volume><fpage>1977</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(01)00110-9</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>I</given-names></name><name><surname>Knoblich</surname><given-names>U</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>J</given-names></name><name><surname>Graybiel</surname><given-names>AM</given-names></name><name><surname>Boyden</surname><given-names>ES</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Moore</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Optogenetic drive of neocortical pyramidal neurons generates fMRI signals that are correlated with spiking activity</article-title><source>Brain Research</source><volume>1511</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.03.011</pub-id><pub-id pub-id-type="pmid">23523914</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Gallopin</surname><given-names>T</given-names></name><name><surname>Dávid</surname><given-names>C</given-names></name><name><surname>Battaglia</surname><given-names>D</given-names></name><name><surname>Geoffroy</surname><given-names>H</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Hillman</surname><given-names>EMC</given-names></name><name><surname>Staiger</surname><given-names>JF</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Classification of NPY-expressing neocortical interneurons</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>3642</fpage><lpage>3659</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0058-09.2009</pub-id><pub-id pub-id-type="pmid">19295167</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Gallopin</surname><given-names>T</given-names></name><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Plaisier</surname><given-names>F</given-names></name><name><surname>Piquet</surname><given-names>J</given-names></name><name><surname>Geoffroy</surname><given-names>H</given-names></name><name><surname>Hepp</surname><given-names>R</given-names></name><name><surname>Naudé</surname><given-names>J</given-names></name><name><surname>Le Gac</surname><given-names>B</given-names></name><name><surname>Egger</surname><given-names>R</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Staiger</surname><given-names>JF</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Seino</surname><given-names>S</given-names></name><name><surname>Roeper</surname><given-names>J</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lactate is an energy substrate for rodent cortical neurons and enhances their firing activity</article-title><source>eLife</source><volume>1</volume><elocation-id>e1424</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.71424</pub-id><pub-id pub-id-type="pmid">34766906</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasischke</surname><given-names>KA</given-names></name><name><surname>Lambert</surname><given-names>EM</given-names></name><name><surname>Panepento</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Gelbard</surname><given-names>HA</given-names></name><name><surname>Burgess</surname><given-names>RW</given-names></name><name><surname>Foster</surname><given-names>TH</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Two-photon NADH imaging exposes boundaries of oxygen diffusion in cortical vascular supply regions</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>31</volume><fpage>68</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2010.158</pub-id><pub-id pub-id-type="pmid">20859293</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawchuk</surname><given-names>MB</given-names></name><name><surname>Ruff</surname><given-names>CF</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Ross</surname><given-names>SE</given-names></name><name><surname>Vazquez</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Optogenetic assessment of VIP, PV, SOM and NOS inhibitory neuron activity and cerebral blood flow regulation in mouse somato-sensory cortex</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>40</volume><fpage>1427</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1177/0271678X19870105</pub-id><pub-id pub-id-type="pmid">31418628</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Toussay</surname><given-names>X</given-names></name><name><surname>Anenberg</surname><given-names>E</given-names></name><name><surname>Lecrux</surname><given-names>C</given-names></name><name><surname>Ferreirós</surname><given-names>N</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Plaisier</surname><given-names>F</given-names></name><name><surname>Chausson</surname><given-names>P</given-names></name><name><surname>Jarlier</surname><given-names>F</given-names></name><name><surname>Burgess</surname><given-names>SA</given-names></name><name><surname>Hillman</surname><given-names>E</given-names></name><name><surname>Tegeder</surname><given-names>I</given-names></name><name><surname>Murphy</surname><given-names>TH</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Ferreiro</surname><given-names>N</given-names></name><name><surname>Burgess</surname><given-names>SA</given-names></name><name><surname>Hillman</surname><given-names>E</given-names></name><name><surname>Tegeder</surname><given-names>I</given-names></name><name><surname>Murphy</surname><given-names>TH</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>COX-2-derived prostaglandin e2 produced by pyramidal neurons contributes to neurovascular coupling in the rodent cerebral cortex</article-title><source>The Journal of Neuroscience</source><volume>35</volume><fpage>11791</fpage><lpage>11810</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0651-15.2015</pub-id><pub-id pub-id-type="pmid">26311764</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecrux</surname><given-names>C</given-names></name><name><surname>Toussay</surname><given-names>X</given-names></name><name><surname>Kocharyan</surname><given-names>A</given-names></name><name><surname>Fernandes</surname><given-names>P</given-names></name><name><surname>Neupane</surname><given-names>S</given-names></name><name><surname>Lévesque</surname><given-names>M</given-names></name><name><surname>Plaisier</surname><given-names>F</given-names></name><name><surname>Shmuel</surname><given-names>A</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pyramidal neurons are “neurogenic hubs” in the neurovascular coupling response to whisker stimulation</article-title><source>The Journal of Neuroscience</source><volume>31</volume><fpage>9836</fpage><lpage>9847</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4943-10.2011</pub-id><pub-id pub-id-type="pmid">21734275</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JMJ</given-names></name><name><surname>Stile</surname><given-names>CL</given-names></name><name><surname>Bice</surname><given-names>AR</given-names></name><name><surname>Rosenthal</surname><given-names>ZP</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>AZ</given-names></name><name><surname>Lee</surname><given-names>JMJ</given-names></name><name><surname>Bauer</surname><given-names>AQ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Opposed hemodynamic responses following increased excitation and parvalbumin-based inhibition</article-title><source>Journal of Cerebral Blood Flow &amp; Metabolism</source><volume>41</volume><fpage>841</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1177/0271678X20930831</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>MZ</given-names></name><name><surname>Steinbach</surname><given-names>P</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Characterization of engineered channelrhodopsin variants with improved properties and kinetics</article-title><source>Biophysical Journal</source><volume>96</volume><fpage>1803</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2008.11.034</pub-id><pub-id pub-id-type="pmid">19254539</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lora</surname><given-names>M</given-names></name><name><surname>Denault</surname><given-names>JB</given-names></name><name><surname>Leduc</surname><given-names>R</given-names></name><name><surname>de Brum-Fernandes</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Systematic pharmacological approach to the characterization of NSAIDs</article-title><source>Prostaglandins, Leukotrienes, and Essential Fatty Acids</source><volume>59</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/s0952-3278(98)90052-7</pub-id><pub-id pub-id-type="pmid">9758208</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Shaik</surname><given-names>MA</given-names></name><name><surname>Kozberg</surname><given-names>MG</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Portes</surname><given-names>JP</given-names></name><name><surname>Timerman</surname><given-names>D</given-names></name><name><surname>Hillman</surname><given-names>EMC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Resting-state hemodynamics are spatiotemporally coupled to synchronized and symmetric neural activity in excitatory neurons</article-title><source>PNAS</source><volume>113</volume><fpage>E8463</fpage><lpage>E8471</lpage><pub-id pub-id-type="doi">10.1073/pnas.1525369113</pub-id><pub-id pub-id-type="pmid">27974609</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madisen</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Koch</surname><given-names>H</given-names></name><name><surname>Zhuo</surname><given-names>J</given-names></name><name><surname>Berenyi</surname><given-names>A</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>Y-WA</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Zanella</surname><given-names>S</given-names></name><name><surname>Kidney</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Hooks</surname><given-names>BM</given-names></name><name><surname>Boyden</surname><given-names>ES</given-names></name><name><surname>Buzsáki</surname><given-names>G</given-names></name><name><surname>Ramirez</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Svoboda</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Turner</surname><given-names>EE</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing</article-title><source>Nature Neuroscience</source><volume>15</volume><fpage>793</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1038/nn.3078</pub-id><pub-id pub-id-type="pmid">22446880</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meurs</surname><given-names>A</given-names></name><name><surname>Portelli</surname><given-names>J</given-names></name><name><surname>Clinckers</surname><given-names>R</given-names></name><name><surname>Balasubramaniam</surname><given-names>A</given-names></name><name><surname>Michotte</surname><given-names>Y</given-names></name><name><surname>Smolders</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Neuropeptide Y increases in vivo hippocampal extracellular glutamate levels through Y1 receptor activation</article-title><source>Neuroscience Letters</source><volume>510</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2012.01.023</pub-id><pub-id pub-id-type="pmid">22285263</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gourine</surname><given-names>AV</given-names></name><name><surname>Rusakov</surname><given-names>DA</given-names></name><name><surname>Attwell</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1619</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1038/nn.4428</pub-id><pub-id pub-id-type="pmid">27775719</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>K</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Ishimoto</surname><given-names>T</given-names></name><name><surname>Sato-Watanabe</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Doi</surname><given-names>M</given-names></name><name><surname>Kametani</surname><given-names>S</given-names></name><name><surname>Tomishima</surname><given-names>Y</given-names></name><name><surname>Ueki</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Kameo</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme</article-title><source>British Journal of Pharmacology</source><volume>133</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0704101</pub-id><pub-id pub-id-type="pmid">11375247</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>SJ</given-names></name><name><surname>MacVicar</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Calcium transients in astrocyte endfeet cause cerebrovascular constrictions</article-title><source>Nature</source><volume>431</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/nature02827</pub-id><pub-id pub-id-type="pmid">15356633</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>K</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name><name><surname>Morham</surname><given-names>SG</given-names></name><name><surname>Ross</surname><given-names>ME</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex</article-title><source>The Journal of Neuroscience</source><volume>20</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-02-00763.2000</pub-id><pub-id pub-id-type="pmid">10632605</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Herron</surname><given-names>P</given-names></name><name><surname>Chhatbar</surname><given-names>PY</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Schramm</surname><given-names>AE</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Kara</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neural correlates of single-vessel haemodynamic responses in vivo</article-title><source>Nature</source><volume>534</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/nature17965</pub-id><pub-id pub-id-type="pmid">27281215</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oversø Hansen</surname><given-names>P</given-names></name><name><surname>Kringelholt</surname><given-names>S</given-names></name><name><surname>Simonsen</surname><given-names>U</given-names></name><name><surname>Bek</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Hypoxia-induced relaxation of porcine retinal arterioles in vitro depends on inducible NO synthase and EP4 receptor stimulation in the perivascular retina</article-title><source>Acta Ophthalmologica</source><volume>93</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1111/aos.12669</pub-id><pub-id pub-id-type="pmid">25619924</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Chin</surname><given-names>J</given-names></name><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Thwin</surname><given-names>MT</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>KO</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>Kreitzer</surname><given-names>A</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name><name><surname>Noebels</surname><given-names>JL</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease</article-title><source>Neuron</source><volume>55</volume><fpage>697</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.07.025</pub-id><pub-id pub-id-type="pmid">17785178</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/nn.2583</pub-id><pub-id pub-id-type="pmid">20581818</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasinetti</surname><given-names>GM</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain</article-title><source>Neuroscience</source><volume>87</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(98)00218-8</pub-id><pub-id pub-id-type="pmid">9740394</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellerin</surname><given-names>L</given-names></name><name><surname>Magistretti</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization</article-title><source>PNAS</source><volume>91</volume><fpage>10625</fpage><lpage>10629</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.22.10625</pub-id><pub-id pub-id-type="pmid">7938003</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrenoud</surname><given-names>Q</given-names></name><name><surname>Geoffroy</surname><given-names>H</given-names></name><name><surname>Gauthier</surname><given-names>B</given-names></name><name><surname>Rancillac</surname><given-names>A</given-names></name><name><surname>Alfonsi</surname><given-names>F</given-names></name><name><surname>Kessaris</surname><given-names>N</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Vitalis</surname><given-names>T</given-names></name><name><surname>Gallopin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Characterization of Type I and Type II nNOS-expressing interneurons in the barrel cortex of mouse</article-title><source>Frontiers in Neural Circuits</source><volume>6</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2012.00036</pub-id><pub-id pub-id-type="pmid">22754499</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>C</given-names></name><name><surname>Komaki</surname><given-names>Y</given-names></name><name><surname>Deàs-Just</surname><given-names>A</given-names></name><name><surname>Le Gac</surname><given-names>B</given-names></name><name><surname>Mouffle</surname><given-names>C</given-names></name><name><surname>Franco</surname><given-names>C</given-names></name><name><surname>Chaperon</surname><given-names>A</given-names></name><name><surname>Vialou</surname><given-names>V</given-names></name><name><surname>Tsurugizawa</surname><given-names>T</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Astrocyte aquaporin mediates a tonic water efflux maintaining brain homeostasis</article-title><source>eLife</source><volume>13</volume><elocation-id>RP95873</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.95873</pub-id><pub-id pub-id-type="pmid">39508543</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rancillac</surname><given-names>A</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Guille</surname><given-names>M</given-names></name><name><surname>Tong</surname><given-names>XK</given-names></name><name><surname>Geoffroy</surname><given-names>H</given-names></name><name><surname>Amatore</surname><given-names>C</given-names></name><name><surname>Arbault</surname><given-names>S</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Glutamatergic control of microvascular tone by distinct gaba neurons in the cerebellum</article-title><source>The Journal of Neuroscience</source><volume>26</volume><fpage>6997</fpage><lpage>7006</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5515-05.2006</pub-id><pub-id pub-id-type="pmid">16807329</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2023">2023</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosehart</surname><given-names>AC</given-names></name><name><surname>Longden</surname><given-names>TA</given-names></name><name><surname>Weir</surname><given-names>N</given-names></name><name><surname>Fontaine</surname><given-names>JT</given-names></name><name><surname>Joutel</surname><given-names>A</given-names></name><name><surname>Dabertrand</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prostaglandin E<sub>2</sub> dilates intracerebral arterioles when applied to capillaries: implications for small vessel diseases</article-title><source>Frontiers in Aging Neuroscience</source><volume>13</volume><elocation-id>695965</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2021.695965</pub-id><pub-id pub-id-type="pmid">34483880</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudolf</surname><given-names>K</given-names></name><name><surname>Eberlein</surname><given-names>W</given-names></name><name><surname>Engel</surname><given-names>W</given-names></name><name><surname>Wieland</surname><given-names>HA</given-names></name><name><surname>Willim</surname><given-names>KD</given-names></name><name><surname>Entzeroth</surname><given-names>M</given-names></name><name><surname>Wienen</surname><given-names>W</given-names></name><name><surname>Beck-Sickinger</surname><given-names>AG</given-names></name><name><surname>Doods</surname><given-names>HN</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226</article-title><source>European Journal of Pharmacology</source><volume>271</volume><fpage>R11</fpage><lpage>R13</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(94)90822-2</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rungta</surname><given-names>RL</given-names></name><name><surname>Osmanski</surname><given-names>BF</given-names></name><name><surname>Boido</surname><given-names>D</given-names></name><name><surname>Tanter</surname><given-names>M</given-names></name><name><surname>Charpak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Light controls cerebral blood flow in naive animals</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14191</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14191</pub-id><pub-id pub-id-type="pmid">28139643</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rungta</surname><given-names>RL</given-names></name><name><surname>Chaigneau</surname><given-names>E</given-names></name><name><surname>Osmanski</surname><given-names>BF</given-names></name><name><surname>Charpak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Vascular compartmentalization of functional hyperemia from the synapse to the pia</article-title><source>Neuron</source><volume>99</volume><fpage>362</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.06.012</pub-id><pub-id pub-id-type="pmid">29937277</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rungta</surname><given-names>RL</given-names></name><name><surname>Zuend</surname><given-names>M</given-names></name><name><surname>Aydin</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Charpak</surname><given-names>S</given-names></name><name><surname>Boido</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Vascular arbors in layer II / III somatosensory cortex</article-title><source>Commun Biol</source><volume>94</volume><elocation-id>855</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02382-w</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sada</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Katsu</surname><given-names>T</given-names></name><name><surname>Otsuki</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epilepsy treatment targeting LDH enzymes with a stiripentol analog to treat epilepsy</article-title><source>Science</source><volume>347</volume><fpage>1362</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1299</pub-id><pub-id pub-id-type="pmid">25792327</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Säfholm</surname><given-names>J</given-names></name><name><surname>Dahlén</surname><given-names>SE</given-names></name><name><surname>Adner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Antagonising EP1 and EP2 receptors reveal that the TP receptor mediates a component of antigen-induced contraction of the guinea pig trachea</article-title><source>European Journal of Pharmacology</source><volume>718</volume><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.08.021</pub-id><pub-id pub-id-type="pmid">24012781</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Säfholm</surname><given-names>J</given-names></name><name><surname>Dahlén</surname><given-names>SE</given-names></name><name><surname>Delin</surname><given-names>I</given-names></name><name><surname>Maxey</surname><given-names>K</given-names></name><name><surname>Stark</surname><given-names>K</given-names></name><name><surname>Cardell</surname><given-names>LO</given-names></name><name><surname>Adner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors</article-title><source>British Journal of Pharmacology</source><volume>168</volume><fpage>794</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02189.x</pub-id><pub-id pub-id-type="pmid">22934927</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Marcheselli</surname><given-names>V</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>9858</fpage><lpage>9870</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2392-05.2005</pub-id><pub-id pub-id-type="pmid">16251433</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>F</given-names></name><name><surname>Barrett</surname><given-names>M</given-names></name><name><surname>Jenny</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Vascular density and distribution in neocortex</article-title><source>NeuroImage</source><volume>197</volume><fpage>792</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.06.046</pub-id><pub-id pub-id-type="pmid">28669910</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>NA</given-names></name><name><surname>Murphy</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hemodynamic responses evoked by neuronal stimulation via channelrhodopsin-2 can be independent of intracortical glutamatergic synaptic transmission</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e29859</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029859</pub-id><pub-id pub-id-type="pmid">22253807</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>NA</given-names></name><name><surname>Klimko</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility</article-title><source>British Journal of Pharmacology</source><volume>176</volume><fpage>1059</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1111/bph.14335</pub-id><pub-id pub-id-type="pmid">29679483</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmuel</surname><given-names>A</given-names></name><name><surname>Yacoub</surname><given-names>E</given-names></name><name><surname>Pfeuffer</surname><given-names>J</given-names></name><name><surname>Van de Moortele</surname><given-names>PF</given-names></name><name><surname>Adriany</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ugurbil</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Sustained negative BOLD, blood flow and oxygen consumption response and its coupling to the positive response in the human brain</article-title><source>Neuron</source><volume>36</volume><fpage>1195</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(02)01061-9</pub-id><pub-id pub-id-type="pmid">12495632</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smetters</surname><given-names>D</given-names></name><name><surname>Majewska</surname><given-names>A</given-names></name><name><surname>Yuste</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Detecting action potentials in neuronal populations with calcium imaging</article-title><source>Methods</source><volume>18</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1006/meth.1999.0774</pub-id><pub-id pub-id-type="pmid">10356353</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Koboldt</surname><given-names>CM</given-names></name><name><surname>Muhammad</surname><given-names>J</given-names></name><name><surname>Zweifel</surname><given-names>BS</given-names></name><name><surname>Shaffer</surname><given-names>A</given-names></name><name><surname>Talley</surname><given-names>JJ</given-names></name><name><surname>Masferrer</surname><given-names>JL</given-names></name><name><surname>Seibert</surname><given-names>K</given-names></name><name><surname>Isakson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Pharmacological analysis of cyclooxygenase-1 in inflammation</article-title><source>PNAS</source><volume>95</volume><fpage>13313</fpage><lpage>13318</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.22.13313</pub-id><pub-id pub-id-type="pmid">9789085</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>Sümbül</surname><given-names>U</given-names></name><name><surname>Graybuck</surname><given-names>LT</given-names></name><name><surname>Collman</surname><given-names>F</given-names></name><name><surname>Seshamani</surname><given-names>S</given-names></name><name><surname>Gala</surname><given-names>R</given-names></name><name><surname>Gliko</surname><given-names>O</given-names></name><name><surname>Elabbady</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Bakken</surname><given-names>TE</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Lein</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Tasic</surname><given-names>B</given-names></name><name><surname>Hawrylycz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell transcriptomic evidence for dense intracortical neuropeptide networks</article-title><source>eLife</source><volume>8</volume><elocation-id>e7889</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.47889</pub-id><pub-id pub-id-type="pmid">31710287</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>QQ</given-names></name><name><surname>Baraban</surname><given-names>SC</given-names></name><name><surname>Prince</surname><given-names>DA</given-names></name><name><surname>Huguenard</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Target-specific neuropeptide Y-ergic synaptic inhibition and its network consequences within the mammalian thalamus</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>9639</fpage><lpage>9649</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-29-09639.2003</pub-id><pub-id pub-id-type="pmid">14573544</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>McConnell</surname><given-names>E</given-names></name><name><surname>Pare</surname><given-names>JF</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Lovatt</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>Y</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glutamate-dependent neuroglial calcium signaling differs between young and adult brain</article-title><source>Science</source><volume>339</volume><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1126/science.1226740</pub-id><pub-id pub-id-type="pmid">23307741</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>S</given-names></name><name><surname>Hasegawa-Ishii</surname><given-names>S</given-names></name><name><surname>Uekawa</surname><given-names>A</given-names></name><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Umegaki</surname><given-names>H</given-names></name><name><surname>Hosokawa</surname><given-names>M</given-names></name><name><surname>Woodward</surname><given-names>DF</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immunohistochemical demonstration of increased prostaglandin F₂α levels in the rat hippocampus following kainic acid-induced seizures</article-title><source>Neuroscience</source><volume>218</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.05.013</pub-id><pub-id pub-id-type="pmid">22609937</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemiya</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Roles of prostaglandin synthesis in excitotoxic brain diseases</article-title><source>Neurochemistry International</source><volume>51</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.05.009</pub-id><pub-id pub-id-type="pmid">17629358</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tammaro</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Hutchings</surname><given-names>SR</given-names></name><name><surname>Smirnov</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Pharmacological evidence for a key role of voltage-gated K+ channels in the function of rat aortic smooth muscle cells</article-title><source>British Journal of Pharmacology</source><volume>143</volume><fpage>303</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0705957</pub-id><pub-id pub-id-type="pmid">15326038</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasic</surname><given-names>B</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>TN</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Jarsky</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Levi</surname><given-names>B</given-names></name><name><surname>Gray</surname><given-names>LT</given-names></name><name><surname>Sorensen</surname><given-names>SA</given-names></name><name><surname>Dolbeare</surname><given-names>T</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Shapovalova</surname><given-names>N</given-names></name><name><surname>Parry</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Madisen</surname><given-names>L</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Hawrylycz</surname><given-names>M</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adult mouse cortical cell taxonomy revealed by single cell transcriptomics</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nn.4216</pub-id><pub-id pub-id-type="pmid">26727548</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thévenaz</surname><given-names>P</given-names></name><name><surname>Ruttimann</surname><given-names>UE</given-names></name><name><surname>Unser</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A pyramid approach to subpixel registration based on intensity</article-title><source>IEEE Transactions on Image Processing</source><volume>7</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1109/83.650848</pub-id><pub-id pub-id-type="pmid">18267377</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournissac</surname><given-names>M</given-names></name><name><surname>Boido</surname><given-names>D</given-names></name><name><surname>Omnès</surname><given-names>M</given-names></name><name><surname>Houssen</surname><given-names>YG</given-names></name><name><surname>Ciobanu</surname><given-names>L</given-names></name><name><surname>Charpak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cranial window for longitudinal and multimodal imaging of the whole mouse cortex</article-title><source>Neurophotonics</source><volume>9</volume><elocation-id>031921</elocation-id><pub-id pub-id-type="doi">10.1117/1.NPh.9.3.031921</pub-id><pub-id pub-id-type="pmid">36159711</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>CHT</given-names></name><name><surname>George</surname><given-names>AG</given-names></name><name><surname>Teskey</surname><given-names>GC</given-names></name><name><surname>Gordon</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Seizures elevate gliovascular unit Ca2+ and cause sustained vasoconstriction</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e136469</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136469</pub-id><pub-id pub-id-type="pmid">33004688</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CJ</given-names></name><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Suganuma</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>KE</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cerebral capillary blood flow upsurge during REM sleep is mediated by A2a receptors</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109558</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109558</pub-id><pub-id pub-id-type="pmid">34407410</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsurumaki</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Higuchi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Marked neuropeptide Y-induced contractions via NPY-Y1 receptor and its desensitization in rat veins</article-title><source>Vascular Pharmacology</source><volume>39</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/s1537-1891(03)00044-2</pub-id><pub-id pub-id-type="pmid">14567071</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsurumaki</surname><given-names>T</given-names></name><name><surname>Muraoka</surname><given-names>O</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Higuchi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Neuropeptide Y-induced contraction and its desensitization through the neuropeptide Y receptor subtype in several rat veins</article-title><source>Journal of Cardiovascular Pharmacology</source><volume>41 Suppl 1</volume><fpage>S23</fpage><lpage>S27</lpage><pub-id pub-id-type="pmid">12688392</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlirova</surname><given-names>H</given-names></name><name><surname>Kılıç</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>P</given-names></name><name><surname>Thunemann</surname><given-names>M</given-names></name><name><surname>Desjardins</surname><given-names>M</given-names></name><name><surname>Saisan</surname><given-names>PA</given-names></name><name><surname>Sakadžić</surname><given-names>S</given-names></name><name><surname>Ness</surname><given-names>TV</given-names></name><name><surname>Mateo</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Weldy</surname><given-names>KL</given-names></name><name><surname>Razoux</surname><given-names>F</given-names></name><name><surname>Vandenberghe</surname><given-names>M</given-names></name><name><surname>Cremonesi</surname><given-names>JA</given-names></name><name><surname>Ferri</surname><given-names>CG</given-names></name><name><surname>Nizar</surname><given-names>K</given-names></name><name><surname>Sridhar</surname><given-names>VB</given-names></name><name><surname>Steed</surname><given-names>TC</given-names></name><name><surname>Abashin</surname><given-names>M</given-names></name><name><surname>Fainman</surname><given-names>Y</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Djurovic</surname><given-names>S</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Silva</surname><given-names>GA</given-names></name><name><surname>Boas</surname><given-names>DA</given-names></name><name><surname>Kleinfeld</surname><given-names>D</given-names></name><name><surname>Buxton</surname><given-names>RB</given-names></name><name><surname>Einevoll</surname><given-names>GT</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Devor</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cell type specificity of neurovascular coupling in cerebral cortex</article-title><source>eLife</source><volume>5</volume><elocation-id>e4315</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.14315</pub-id><pub-id pub-id-type="pmid">27244241</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voutsinos-Porche</surname><given-names>B</given-names></name><name><surname>Bonvento</surname><given-names>G</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Steiner</surname><given-names>P</given-names></name><name><surname>Welker</surname><given-names>E</given-names></name><name><surname>Chatton</surname><given-names>JY</given-names></name><name><surname>Magistretti</surname><given-names>PJ</given-names></name><name><surname>Pellerin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex</article-title><source>Neuron</source><volume>37</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(02)01170-4</pub-id><pub-id pub-id-type="pmid">12546822</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Wolf</surname><given-names>R</given-names></name><name><surname>Zeitschel</surname><given-names>U</given-names></name><name><surname>Rossner</surname><given-names>S</given-names></name><name><surname>Petersén</surname><given-names>Å</given-names></name><name><surname>Leavitt</surname><given-names>BR</given-names></name><name><surname>Kästner</surname><given-names>F</given-names></name><name><surname>Rothermundt</surname><given-names>M</given-names></name><name><surname>Gärtner</surname><given-names>U-T</given-names></name><name><surname>Gündel</surname><given-names>D</given-names></name><name><surname>Schlenzig</surname><given-names>D</given-names></name><name><surname>Frerker</surname><given-names>N</given-names></name><name><surname>Schade</surname><given-names>J</given-names></name><name><surname>Manhart</surname><given-names>S</given-names></name><name><surname>Rahfeld</surname><given-names>J-U</given-names></name><name><surname>Demuth</surname><given-names>H-U</given-names></name><name><surname>von Hörsten</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery</article-title><source>Journal of Neurochemistry</source><volume>135</volume><fpage>1019</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1111/jnc.13378</pub-id><pub-id pub-id-type="pmid">26442809</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Andreasson</surname><given-names>KI</given-names></name><name><surname>Kaufmann</surname><given-names>WE</given-names></name><name><surname>Barnes</surname><given-names>CA</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids</article-title><source>Neuron</source><volume>11</volume><fpage>371</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(93)90192-t</pub-id><pub-id pub-id-type="pmid">8352945</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>W</given-names></name><name><surname>Shiraki</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever</article-title><source>The Journal of Neuroscience</source><volume>21</volume><fpage>2669</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-08-02669.2001</pub-id><pub-id pub-id-type="pmid">11306620</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisel</surname><given-names>A</given-names></name><name><surname>Muñoz-Manchado</surname><given-names>AB</given-names></name><name><surname>Codeluppi</surname><given-names>S</given-names></name><name><surname>Lönnerberg</surname><given-names>P</given-names></name><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Juréus</surname><given-names>A</given-names></name><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Munguba</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Rolny</surname><given-names>C</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Brain structure: cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq</article-title><source>Science</source><volume>347</volume><fpage>1138</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1934</pub-id><pub-id pub-id-type="pmid">25700174</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>DY</given-names></name><name><surname>Raichle</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Disease and the brain’s dark energy</article-title><source>Nature Reviews Neurology</source><volume>6</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.198</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>W-P</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Jia</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Synaptic-like transmission between neural axons and arteriolar smooth muscle cells drives cerebral neurovascular coupling</article-title><source>Nature Neuroscience</source><volume>27</volume><fpage>232</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s41593-023-01515-0</pub-id><pub-id pub-id-type="pmid">38168932</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N</given-names></name><name><surname>Gordon</surname><given-names>GRJ</given-names></name><name><surname>Feighan</surname><given-names>D</given-names></name><name><surname>MacVicar</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transient swelling, acidification, and mitochondrial depolarization occurs in neurons but not astrocytes during spreading depression</article-title><source>Cerebral Cortex</source><volume>20</volume><fpage>2614</fpage><lpage>2624</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhq018</pub-id><pub-id pub-id-type="pmid">20176688</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonta</surname><given-names>M</given-names></name><name><surname>Angulo</surname><given-names>MC</given-names></name><name><surname>Gobbo</surname><given-names>S</given-names></name><name><surname>Rosengarten</surname><given-names>B</given-names></name><name><surname>Hossmann</surname><given-names>KA</given-names></name><name><surname>Pozzan</surname><given-names>T</given-names></name><name><surname>Carmignoto</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation</article-title><source>Nature Neuroscience</source><volume>6</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nn980</pub-id><pub-id pub-id-type="pmid">12469126</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, male and female)</td><td align="left" valign="bottom">C57BL/6RJ, Wild type</td><td align="left" valign="bottom">Janvier Labs</td><td align="left" valign="bottom">C57BL/6RJ</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, male and female)</td><td align="left" valign="bottom">B6.129P2- <italic>Emx1<sup>tm1(cre)Krj</sup>/J</italic>, Emx1 <sup>Cre/Cre</sup></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12151506/">12151506</ext-link>; <xref ref-type="bibr" rid="bib31">Gorski et al., 2002</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:005628">IMSR_JAX:005628</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>, male and female)</td><td align="left" valign="bottom">B6.129P2- Gt(ROSA)26Sor<sup>tm32(CAG-COP4*H134R/EYFP)Hze</sup>, Gt(ROSA)26Sor <sup>ChR2(H134R)-EYFP/ ChR2(H134R)-EYFP</sup></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22446880/">22446880</ext-link>; <xref ref-type="bibr" rid="bib51">Madisen et al., 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:024109">IMSR_JAX:024109</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Slc17a7</italic> external sense PCR primer<break/>(vGluT1)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GGCTCCTTTTTCTGGGGCTAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Slc17a7</italic> external antisense PCR primer<break/>(vGluT1)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CCAGCCGACTCCGTTCTAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Slc17a7</italic> internal sense PCR primer<break/>(vGluT1)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">ATTCGCAGCCAACAGGGTCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Slc17a7</italic> internal antisense PCR primer<break/>(vGluT1)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TGGCAAGCAGGGTATGTGAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad2</italic> external sense PCR primer<break/>(GAD 65)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19295167/">19295167</ext-link>; <xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CCAAAAGTTCACGGGCGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad2</italic> external antisense PCR primer<break/>(GAD 65)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19295167/">19295167</ext-link>; <xref ref-type="bibr" rid="bib41">Karagiannis et al., 2009</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TCCTCCAGATTTTGCGGTTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad2</italic> internal sense PCR primer<break/>(GAD 65)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22754499/">22754499</ext-link>; <xref ref-type="bibr" rid="bib63">Perrenoud et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CACCTGCGACCAAAAACCCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad2</italic> internal antisense PCR primer<break/>(GAD 65)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22754499/">22754499</ext-link>; <xref ref-type="bibr" rid="bib63">Perrenoud et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GATTTTGCGGTTGGTCTGCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad1</italic> external sense PCR primer<break/>(GAD 67)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12196560/">12196560</ext-link>; <xref ref-type="bibr" rid="bib26">Férézou et al., 2002</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TACGGGGTTCGCACAGGTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad1</italic> external antisense PCR primer<break/>(GAD 67)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12196560/">12196560</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CCCAGGCAGCATCCACAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad1</italic> internal sense PCR primer<break/>(GAD 67)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CCCAGAAGTGAAGACAAAAGGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gad1</italic> internal antisense PCR primer<break/>(GAD 67)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link>; <xref ref-type="bibr" rid="bib10">Cabezas et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AATGCTCCGTAAACAGTCGTGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs1</italic> external sense PCR primer<break/>(COX-1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">ATCCCTGTTGTTACTATCCGTGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs1</italic> external antisense PCR primer<break/>(COX-1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TGTGGGGCAGTCTTTGGGTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs1</italic> internal sense PCR primer<break/>(COX-1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AGGGTGTCTGTGTCCGCTTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs1</italic> internal antisense PCR primer<break/>(COX-1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GGCTGGGGATAAGGTTGGAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs2</italic> external sense PCR primer<break/>(COX-2)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21734275/">21734275</ext-link>; <xref ref-type="bibr" rid="bib46">Lecrux et al., 2011</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CTGAAGCCCACCCCAAACAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs2</italic> external antisense PCR primer<break/>(COX-2)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29985318/">29985318</ext-link>; <xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CCTTATTTCCCTTCACACCCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs2</italic> internal sense PCR primer<break/>(COX-2)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29985318/">29985318</ext-link>; <xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AACAACATCCCCTTCCTGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptgs2</italic> internal antisense PCR primer<break/>(COX-2)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29985318/">29985318</ext-link>; <xref ref-type="bibr" rid="bib21">Devienne et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TGGGAGTTGGGCAGTCATCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges</italic> external sense PCR primer<break/>(mPGES1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GCCTGGTGATGGAGAGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges</italic> external antisense PCR primer<break/>(mPGES1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GGAGCGAAGGCGTGGGTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges</italic> internal sense PCR primer<break/>(mPGES1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AGATGAGGCTGCGGAAGAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges</italic> internal antisense PCR primer<break/>(mPGES1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CACGAAGCCGAGGAAGAGGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges2</italic> external sense PCR primer<break/>(mPGES1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CGACTTCCACTCCCTGCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges2</italic> external antisense PCR primer<break/>(mPGES2)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CATCTCCTCCGTCCTGGCTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges2</italic> internal sense PCR primer<break/>(mPGES2)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GAGGTGAATCCCGTGAGAAGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges2</italic> internal antisense PCR primer<break/>(mPGES2)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TTCCTTCCCGCCATACATCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges3</italic> external sense PCR primer<break/>(cPGES)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TCCAAGCATAAAAGAACAGACAGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges3</italic> external antisense PCR primer<break/>(cPGES)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TGGCATCTTTTCATCATCACTGTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges3</italic> internal sense PCR primer<break/>(cPGES)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TAACAAAGGAAAGGGCAAAGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ptges3</italic> internal antisense PCR primer<break/>(cPGES)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CATCATCTGCTCCATCTACTTCTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Prxl2b</italic> external sense PCR primer<break/>(PM-PGFS)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AGGAGTTTCTGGATGGTGGTTAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Prxl2b</italic> external antisense PCR primer<break/>(PM-PGFS)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CACCTCCCACACACCTCTTCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Prxl2b</italic> internal sense PCR primer<break/>(PM-PGFS)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">ACCTGTTCGTGATGTAGCCTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Prxl2b</italic> internal antisense PCR primer<break/>(PM-PGFS)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CTGGGGTGGCTTGCTGGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Akr1b1</italic> external sense PCR primer<break/>(Akr1b3)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CAGAATGAGAAGGAGGTGGGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Akr1b1</italic> external antisense PCR primer<break/>(Akr1b3)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TTGAAGTTGGAGACACCGATTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Akr1b1</italic> internal sense PCR primer<break/>(Akr1b3)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CAAGGAGCAGGTGGTGAAGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Akr1b1</italic> internal antisense PCR primer<break/>(Akr1b3)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CATAGCCGTCCAAGTGTCCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cbr1</italic> external sense PCR primer<break/>(CBR1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AACCCGCAGAGCATTCGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cbr1</italic> external antisense PCR primer<break/>(CBR1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GCCAACCTTCTTCCGCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cbr1</italic> internal sense PCR primer<break/>(CBR1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CAATGACGACACCCCCTTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cbr1</italic> internal antisense PCR primer<break/>(CBR1)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CTCCTCTGTGATGGTCTCGCTT</named-content></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rhod-2</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">20777</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">9,11-dideoxy-9α,11α-methanoepoxy prostaglandin F2α</td><td align="left" valign="bottom">Enzo</td><td align="left" valign="bottom">BML-PG023</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tetrodotoxin</td><td align="left" valign="bottom">Latoxan</td><td align="left" valign="bottom">L8503</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">D-(-)–2-amino-5-phosphonopentanoic acid</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">HB0225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">6,7-dinitroquinoxaline-2,3-dione</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">HB0262</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LY367385</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">HB0398</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-methyl-6-(phenylethynyl)pyridine</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">HB0426</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Indomethacin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">I7378</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SC-560</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">S2064</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NS-398</td><td align="left" valign="bottom">Enzo</td><td align="left" valign="bottom">BML-EI261</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ONO-8130</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">5406</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-798,106</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">11129</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AL8810</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">16735</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PGE2</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">HB3460</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sulprostone</td><td align="left" valign="bottom">Cayman chemical</td><td align="char" char="." valign="bottom">14765</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BIBP3226</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">2707</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HET0016</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">SML2416</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">paxilline</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">2006</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dithiothreitol</td><td align="left" valign="bottom">VWR</td><td align="char" char="." valign="bottom">443852 A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Primer &quot;random&quot;</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">11034731001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">dNTPs</td><td align="left" valign="bottom">GE Healthcare Life Sciences</td><td align="char" char="hyphen" valign="bottom">28-4065-52</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mineral Oil</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">M5904</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RNasin Ribonuclease Inhibitors</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">N2511</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SuperScript II Reverse Transcriptase</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">18064014</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Taq DNA Polymerase</td><td align="left" valign="bottom">Qiagen</td><td align="char" char="." valign="bottom">201205</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Pclamp v 10.2</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_011323">SCR_011323</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Matlab v 2018b</td><td align="left" valign="bottom">MathWorks</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_001622">SCR_001622</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism v 7</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImagingWorkbench v 6.1</td><td align="left" valign="bottom">INDEC Systems</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22743772/">22743772</ext-link>; <xref ref-type="bibr" rid="bib76">Schindelin et al., 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R v 4.3.0</td><td align="left" valign="bottom">R Core Team</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_001905">SCR_001905</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Vibratome</td><td align="left" valign="bottom">Leica</td><td align="left" valign="bottom">VT1000S RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_016495">SCR_016495</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Upright microscope</td><td align="left" valign="bottom">Olympus</td><td align="left" valign="bottom">BX51WI</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dual port module</td><td align="left" valign="bottom">Olympus</td><td align="left" valign="bottom">WI-DPMC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">60 x Objective</td><td align="left" valign="bottom">Olympus</td><td align="left" valign="bottom">LUMPlan Fl /IR 60 x/0.90 W</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">40 x Objetive</td><td align="left" valign="bottom">Olympus</td><td align="left" valign="bottom">LUMPlan Fl /IR 40 x/0.80 W</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">sCMOS camera</td><td align="left" valign="bottom">Hamamatsu</td><td align="left" valign="bottom">ORCA-Flash4.0</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Axopatch 200B</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_018866">SCR_018866</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Digidata 1440 A</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_021038">SCR_021038</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S900 stimulator</td><td align="left" valign="bottom">Dagan corporation</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">pE-2</td><td align="left" valign="bottom">CoolLED</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Excitation filter</td><td align="left" valign="bottom">Semrock</td><td align="left" valign="bottom">HC 392/474/554/635</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dichroic mirror</td><td align="left" valign="bottom">Semrock</td><td align="left" valign="bottom">BS 409/493/573/652</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Emission filter</td><td align="left" valign="bottom">Semrock</td><td align="left" valign="bottom">HC 432/515/595/730</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">780 nm Collimated LED</td><td align="left" valign="bottom">Thorlabs</td><td align="left" valign="bottom">M780L3-C1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dodt Gradient Contrast</td><td align="left" valign="bottom">Luigs and Neumann</td><td align="char" char="ndash" valign="bottom">200–100 200 0155</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Beam splitter</td><td align="left" valign="bottom">Semrock</td><td align="char" char="." valign="bottom">725 DCSPXR</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Analogic CCD camera</td><td align="left" valign="bottom">Sony</td><td align="left" valign="bottom">XC ST-70 CE</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102424.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uhlirova</surname><given-names>Hana</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Faculty of Mechanical Engineering, Brno University of Technology and Institute of Physical Engineering</institution><country>Czech Republic</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This study presents <bold>important</bold> findings on the role of pyramidal cells driving vasoconstriction in brain arteries through a COX-2/PGE2 pathway, with additional contributions from NPY (interneurons) and 20-HETE (astrocytes). Optogenetic stimulation of cortical pyramidal neurons induces vasoconstriction, potentially leading to oxygen and nutrient undersupply in regions with sustained activation - a mechanism potentially relevant under pathological conditions. The authors provide <bold>convincing</bold> evidence from brain slice experiments and some in vivo data from anesthetized animals, carefully discussing the strengths and limitations of both approaches.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102424.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>SNeuronal activity spatiotemporal fine-tuning of cerebral blood flow balances metabolic demands of changing neuronal activity with blood supply. Several 'feed-forward' mechanisms have been described that contribute to activity-dependent vasodilation as well as vasoconstriction leading to a reduction in perfusion. Involved messengers are ionic (K+), gaseous (NO), peptides (e.g., NPY, VIP) and other messengers (PGE2, GABA, glutamate, norepinephrine) that target endothelial cells, smooth muscle cells, or pericytes. Contributions of the respective signaling pathways likely vary across brain regions or even within specific brain regions (e.g., across cortex) and are likely influenced by the brain's physiological state (resting, active, sleeping) or pathological departures from normal physiology.</p><p>The manuscript &quot;Elevated pyramidal cell firing orchestrates arteriolar vasoconstriction through COX-2-derived prostaglandin E2 signaling&quot; by B. Le Gac, et al. investigates mechanisms leading to activity-dependent arteriole constriction. Here, mainly working in brain slices from mice expressing channelrhodopsin 2 (ChR2) in all excitatory neurons (Emx1-Cre; Ai32 mice), the authors show that strong optogenetic stimulation of cortical pyramidal neurons is leading to constriction that is mediated through the cyclooxygenase-2 / prostaglandin E2 / EP1 and EP3 receptor pathway with contribution of NPY-releasing interneurons and astrocytes releasing 20-HETE. Specifically, using patch clamp, the authors show that 10-s optogenetic stimulation at 10 and 20 Hz leads to vasoconstriction (Figure 1), in line with a stimulation frequency-dependent increase in somatic calcium (Figure 2). The vascular effects were abolished in presence in TTX and significantly reduced in presence of glutamate receptor antagonists (Figure 3). The authors further show with RT-PCR on RNA isolated from patched cells that ~50% of analyzed cells express COX-1 or -2 and other enzymes required to produce PGE2 or PGF2a (Figure 4). Further, blockade of COX-1 and -2 (indomethacin), or COX-2 (NS-398) abolishes constriction. In animals with chronic cranial window that were anesthetized with ketamine and medetomidine, 10-s long optogenetic stimulation at 10 Hz leads to considerable constriction, which is reduced in presence of indomethacin. Blockade of EP1 and EP3 receptors leads to significant reduction of the constriction in slices (Figure 5). Finally, the authors show that blockade of 20-HETE synthesis caused moderate and NPY Y1 receptor blockade a complete reduction of constriction.</p><p>The mechanistic analysis of neurovascular coupling mechanisms as exemplified here will guide further in-vivo studies and has important implications for human neuroimaging in health and disease. Most of the data in this manuscript uses brain slices as experimental model which contrasts with neurovascular imaging studies performed in awake (headfixed) animals. However, the slice preparation allows for patch clamp as well as easy drug application and removal. Further, the authors discuss their results in view of differences between brain slices and in vivo observations experiments, including the absence of vascular tone as well as blood perfusion required for metabolite (e.g., PGE2) removal, and the presence of network effects in the intact brain. The manuscript and figures present the data clearly; regarding the presented mechanism, the data supports the authors conclusions. Some of the data was generated in vivo in head-fixed animals under anesthesia; in this regard, the authors should revise introduction and discussion to include the important distinction between studies performed in slices, or in acute or chronic in-vivo preparations under anesthesia reduced network activity and reduced or blockade of neuromodulation, or in awake animals (virtually undisturbed network and neuromodulatory activity). Further, while discussed to some extent, the authors could improve their manuscript by more clearly stating if they expect the described mechanism to contribute to CBF regulation under 'resting state conditions' (i.e., in absence of any stimulus), during short or sustained (e.g., visual, tactile) stimulation, or if this mechanism is mainly relevant under pathological conditions; especially in context of the optogenetic stimulation paradigm being used (10-s long stimulation of many pyramidal neurons at moderate-high frequencies) and the fact that constriction leading to undersupply in response to strongly increased neuronal activity seems counterintuitive?</p><p>The authors have addressed all comments, and I appreciate their insightful discussion and revision of the manuscript.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102424.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The present study by Le Gac et al. investigates the vasoconstriction of cerebral arteries during neurovascular coupling. It proposes that pyramidal neurons firing at high frequency lead to prostaglandin E2 (PGE2) release and activation of arteriolar EP1 and EP3 receptors, causing smooth muscle cell contraction. The authors further claim that interneurons and astrocytes also contribute to the vasoconstriction via neuropeptide Y (NPY) and 20-hydroxyeicosatetraenoic acid (20-HETE) release, respectively. The study mainly uses brain slices and pharmacological tools in combination with Emx1-Cre;Ai32 transgenic mice expressing the H134R variant of channelrhodopsin-2 (ChR2) in the cortical glutamatergic neurons for precise photoactivation. Stimulation with 470 nm light using 10-second trains of 5-ms pulses at frequencies from 1-20 Hz revealed small constrictions at 10 Hz and robust constrictions at 20 Hz, which were abolished by TTX and partially inhibited by a cocktail of glutamate receptor antagonists. Inhibition of cyclooxygenase-1 (COX-1) or -2 (COX-2) by indomethacin blocked the constriction both ex vivo (slices) and in vivo (pial artery), and inhibition of EP1 and EP3 showed the same effect ex vivo. Single-cell RT-PCR from patched neurons confirmed the presence of the PGE2 synthesis pathway. While the data are convincing, the overall experimental setting presents some limitations. How is the activation protocol comparable to physiological firing frequency? The delay (minutes) between the stimulation and the constriction appears contradictory to the proposed pathway, which would be expected to occur rapidly. The experiments are conducted in the absence of vascular &quot;tone,&quot; which further questions the significance of the findings. Some of the targets investigated are expressed by multiple cell types, which makes the interpretation difficult; for example, cyclooxygenases are also expressed by endothelial cells. Finally, how is the complete inhibition of the constriction by the NPY Y1 receptor antagonist BIBP3226 consistent with a direct effect of PGE2 and 20-HETE in arterioles? Overall, the manuscript is well-written with clear data, but the interpretation and physiological relevance have some limitations. However, vasoconstriction is a rather understudied phenomenon in neurovascular coupling, and the present findings may be of significance in the context of pathological brain hypoperfusion.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102424.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Le Gac</surname><given-names>Benjamin</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne University, CNRS, INSERM</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Tournissac</surname><given-names>Marine</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne University, CNRS, INSERM</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Belzic</surname><given-names>Esther</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne University, CNRS, INSERM</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Picaud</surname><given-names>Sandrine</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne Université Campus Jussieu</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Dusart</surname><given-names>Isabelle</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne University, CNRS, INSERM</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Soula</surname><given-names>Hédi</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne Université, INSERM</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dongdong</given-names></name><role specific-use="author">Author</role><aff><institution>Sorbonne Université, Institute of Biology Paris Seine, Neuroscience Paris Seine, CNRS UMR8246, INSERM U1130</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Charpak</surname><given-names>Serge</given-names></name><role specific-use="author">Author</role><aff><institution>Institut de la Vision</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Cauli</surname><given-names>Bruno</given-names></name><role specific-use="author">Author</role><aff><institution>French National Centre for Scientific Research</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Neuronal activity spatiotemporal fine-tuning of cerebral blood flow balances metabolic demands of changing neuronal activity with blood supply. Several 'feed-forward' mechanisms have been described that contribute to activity-dependent vasodilation as well as vasoconstriction leading to a reduction in perfusion. Involved messengers are ionic (K+), gaseous (NO), peptides (e.g., NPY, VIP), and other messengers (PGE2, GABA, glutamate, norepinephrine) that target endothelial cells, smooth muscle cells, or pericytes. Contributions of the respective signaling pathways likely vary across brain regions or even within specific brain regions (e.g., across the cortex) and are likely influenced by the brain's physiological state (resting, active, sleeping) or pathological departures from normal physiology.</p><p>The manuscript &quot;Elevated pyramidal cell firing orchestrates arteriolar vasoconstriction through COX-2derived prostaglandin E2 signaling&quot; by B. Le Gac, et al. investigates mechanisms leading to activitydependent arteriole constriction. Here, mainly working in brain slices from mice expressing channelrhodopsin 2 (ChR2) in all excitatory neurons (Emx1-Cre; Ai32 mice), the authors show that strong optogenetic stimulation of cortical pyramidal neurons leads to constriction that is mediated through the cyclooxygenase-2 / prostaglandin E2 / EP1 and EP3 receptor pathway with contribution of NPY-releasing interneurons and astrocytes releasing 20-HETE. Specifically, using a patch clamp, the authors show that 10-s optogenetic stimulation at 10 and 20 Hz leads to vasoconstriction (Figure 1), in line with a stimulation frequency-dependent increase in somatic calcium (Figure 2). The vascular effects were abolished in the presence of TTX and significantly reduced in the presence of glutamate receptor antagonists (Figure 3). The authors further show with RT-PCR on RNA isolated from patched cells that ~50% of analyzed cells express COX-1 or -2 and other enzymes required to produce PGE2 or PGF2a (Figure 4). Further, blockade of COX-1 and -2 (indomethacin), or COX-2 (NS-398) abolishes constriction. In animals with chronic cranial windows that were anesthetized with ketamine and medetomidine, 10-s long optogenetic stimulation at 10 Hz leads to considerable constriction, which is reduced in the presence of indomethacin. Blockade of EP1 and EP3 receptors leads to a significant reduction of the constriction in slices (Figure 5). Finally, the authors show that blockade of 20-HETE synthesis caused moderate and NPY Y1 receptor blockade a complete reduction of constriction.</p><p>The mechanistic analysis of neurovascular coupling mechanisms as exemplified here will guide further in-vivo studies and has important implications for human neuroimaging in health and disease. Most of the data in this manuscript uses brain slices as an experimental model which contrasts with neurovascular imaging studies performed in awake (headfixed) animals. However, the slice preparation allows for patch clamp as well as easy drug application and removal. Further, the authors discuss their results in view of differences between brain slices and in vivo observations experiments, including the absence of vascular tone as well as blood perfusion required for metabolite (e.g., PGE2) removal, and the presence of network effects in the intact brain. The manuscript and figures present the data clearly; regarding the presented mechanism, the data supports the authors' conclusions.</p></disp-quote><p>We thank the reviewer for his/her supportive comments as well as for pointing out pros and cons of the brain slice preparation.</p><disp-quote content-type="editor-comment"><p>Some of the data was generated in vivo in head-fixed animals under anesthesia; in this regard, the authors should revise the introduction and discussion to include the important distinction between studies performed in slices, or in acute or chronic in-vivo preparations under anesthesia reduced network activity and reduced or blockade of neuromodulation, or in awake animals (virtually undisturbed network and neuromodulatory activity).</p></disp-quote><p>We have now added a paragraph in the introduction (lines 52-64) to highlight the distinction between ex vivo and in vivo models. We now also discuss that anesthetized animals exhibit slower NVC (Line 308-309).</p><disp-quote content-type="editor-comment"><p>Further, while discussed to some extent, the authors could improve their manuscript by more clearly stating if they expect the described mechanism to contribute to CBF regulation under 'resting state conditions' (i.e., in the absence of any stimulus), during short or sustained (e.g., visual, tactile) stimulation, or if this mechanism is mainly relevant under pathological conditions; especially in the context of the optogenetic stimulation paradigm being used (10-s long stimulation of many pyramidal neurons at moderate-high frequencies) and the fact that constriction leading to undersupply in response to strongly increased neuronal activity seems counterintuitive?</p></disp-quote><p>We now discuss more extensively the physiological relevance (lines 422-434 and 436-439) and the conditions where the described mechanisms of neurogenic vasoconstriction may occur.</p><p>We agree with the reviewer that vasoconstriction in response to a large increase in neuronal activity is counterintuitive as it leads to undersupply despite an increased energy demand. We now discuss its potential physio/pathological role in attenuating neuronal activity by reducing energy supply (lines 453-464).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>The present study by Le Gac et al. investigates the vasoconstriction of cerebral arteries during neurovascular coupling. It proposes that pyramidal neurons firing at high frequency lead to prostaglandin E2 (PGE2) release and activation of arteriolar EP1 and EP3 receptors, causing smooth muscle cell contraction. The authors further claim that interneurons and astrocytes also contribute to vasoconstriction via neuropeptide Y (NPY) and 20-hydroxyeicosatetraenoic acid (20-HETE) release, respectively. The study mainly uses brain slices and pharmacological tools in combination with Emx1Cre; Ai32 transgenic mice expressing the H134R variant of channelrhodopsin-2 (ChR2) in the cortical glutamatergic neurons for precise photoactivation. Stimulation with 470 nm light using 10-second trains of 5-ms pulses at frequencies from 1-20 Hz revealed small constrictions at 10 Hz and robust constrictions at 20 Hz, which were abolished by TTX and partially inhibited by a cocktail of glutamate receptor antagonists. Inhibition of cyclooxygenase-1 (COX-1) or -2 (COX-2) by indomethacin blocked the constriction both ex vivo (slices) and in vivo (pial artery), and inhibition of EP1 and EP3 showed the same effect ex vivo. Single-cell RT-PCR from patched neurons confirmed the presence of the PGE2 synthesis pathway.</p><p>While the data are convincing, the overall experimental setting presents some limitations. How is the activation protocol comparable to physiological firing frequency?</p></disp-quote><p>As also suggested by Reviewer #1 we have now discussed more extensively the physiological relevance of our observations (lines 422-434 and 436-439).</p><disp-quote content-type="editor-comment"><p>The delay (minutes) between the stimulation and the constriction appears contradictory to the proposed pathway, which would be expected to occur rapidly. The experiments are conducted in the absence of vascular &quot;tone,&quot; which further questions the significance of the findings.</p></disp-quote><p>The slow kinetics observed ex vivo are probably due to the low recording temperature and the absence of pharmacologically induced vascular tone, as already discussed (lines 312-317). Furthermore, as recommended by reviewer #1, we have presented the advantages and limitations of ex vivo and in vivo approaches (lines 52-64).</p><disp-quote content-type="editor-comment"><p>Some of the targets investigated are expressed by multiple cell types, which makes the interpretation difficult; for example, cyclooxygenases are also expressed by endothelial cells.</p></disp-quote><p>Under normal conditions, endothelial cells only express COX-1 and barely COX-2, whose expression is essentially observed in pyramidal cells (see Tasic et al. 2016, Zeisel et al. 2015, Lacroix et al., 2015). As pointed out by Reviewer # 1, our ex vivo pharmacological data clearly indicate that vasoconstriction is mostly due to COX-2 activity, and to a much lesser extent to COX-1. Since it is well established that the previously described vascular effects of pyramidal cells are essentially mediated by COX-2 activity (Iadecola et al., 2000; Lecrux et al., 2011; Lacroix et al., 2015), we are quite confident that vasoconstriction described here is mainly due COX-2 activity of pyramidal cells.</p><disp-quote content-type="editor-comment"><p>Finally, how is the complete inhibition of the constriction by the NPY Y1 receptor antagonist BIBP3226 consistent with a direct effect of PGE2 and 20-HETE in arterioles?</p></disp-quote><p>We agree with both reviewers that the complete blockade of the constriction by the NPY Y1 receptor antagonist BIBP3226 needs to be more carefully discussed. We have now included in the discussion the possible involvement of Y1 receptors in pyramidal cells, which could promote glutamate release and possibly COX-2, thereby contributing to PGE2 and 20-HETE signaling (lines 402-409).</p><disp-quote content-type="editor-comment"><p>Overall, the manuscript is well-written with clear data, but the interpretation and physiological relevance have some limitations. However, vasoconstriction is a rather understudied phenomenon in neurovascular coupling, and the present findings may be of significance in the context of pathological brain hypoperfusion.</p></disp-quote><p>We thank the reviewer for his/her comment and suggestions, which have helped us to improve our manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>Methods:</p><p>It is not clear if brain slices (or animals) underwent one, two, or several optogenetic stimulations - especially for experiments where 'control' is compared to 'treated' - does this data come from the same vessels (before and after treatment) or from two independent groups of vessels? If repeated stimulations are performed, do these repeated stimulations cause the same vascular response?</p></disp-quote><p>As indicated in the Materials and Methods section, line 543: “Only one arteriole was monitored per slice” implies that the comparisons between the ‘control’ and ‘treated’ groups were made from independent groups of vessels. To clarify this point, we have added “receiving a single optogenetic or pharmacological stimulation” to this sentence lines 543-544.</p><p>For in vivo experiments, animals underwent 10-20 optogenetic stimulations with a 5-minute interstimulus interval during an experiment lasting 2 hours for maximum. Trials from the same vessel were averaged (with a 0.1 s interpolation) for analysis, and the mean per vessels is presented in the graphics.</p><disp-quote content-type="editor-comment"><p>Figure 2:</p><p>Can the authors speculate about the cause for the slow increase in indicator fluorescence from minute 1.5 onward, which seems dependent on stimulation frequency? Is this increase also present when slices from a ChR2-negative animal undergo the same stimulation paradigm?</p></disp-quote><p>Rhod2 was delivered by the patch pipette as indicated in the Materials and Methods section (line 514). Although a period of “at least 15 min after passing in whole-cell configuration to allow for somatic diffusion of the dye” (line 551-552) was observed, this single-wavelength Ca2+ indicator likely continued to diffuse into the cells during the optical recording thereby, inducing a slight increase in delta F/F0, which is consistent with the positive slopes of the mean fluorescence changes observed during the 30-s control baseline (Fig. 2b).</p><disp-quote content-type="editor-comment"><p>Figure 4: Why did the authors include panel (a) here? Also, do the authors observe that cells with different COX-1 or -2 expression profiles show different (electrical, morphological) properties?</p></disp-quote><p>The purpose of panel (a) in Fig. 4 was to ensure the regular spiking electrophysiological phenotype of the pyramidal neurons whose cytoplasm was harvested for subsequent RT-PCR analysis. Despite our efforts, we found no difference in the 32 electrophysiological features between COX-1 or COX-2 positive and negative cells. This is now clearly stated in the result section (lines 210-212) and a supplementary table of electrophysiological features is now provided. Because it is difficult to determine the morphology of neurons analyzed by single-cell RT-PCR (Devienne et al. 2018), these cells were not processed for biocytin labeling.</p><disp-quote content-type="editor-comment"><p>Figure 5: (1) Maybe the authors could highlight panels b-f as in vivo experiments to emphasize that these are in-vivo observations while the other experiments (especially panels g, h) are made in slices?</p></disp-quote><p>We thank the reviewer for this suggestion. A black frame is now depicted in Figure 5 to emphasize in vivo experiments.</p><disp-quote content-type="editor-comment"><p>(2) What is the power of the optogenetic stimulus in this experiment?</p></disp-quote><p>The power of the optogenetic stimulus was 38 mW/mm<sup>2</sup> in ex vivo experiments (see Line 527). For in vivo experiments, 1 mW pulses of 5 ms were used, the intensity being measured at the fiber end. We now provide the information for in vivo experiments in the Methods lines 639-640.</p><disp-quote content-type="editor-comment"><p>(3) Experiments were performed with Fluorescein-Dextran at 920-nm excitation which would overlap with EYFP fluorescence from the ChR2-EYFP transgene. Did the authors encounter any issues with crosstalk between the two labels?</p></disp-quote><p>Crosstalk between EYFP and fluorescein fluorescence was indeed an issue. This is why arterioles were monitored at the pial level to avoid fluorescence contamination from the cortical parenchyma. Because of the perivascular space around pial arterioles, it was possible to measure vessel diameter without pollution for the parenchyma (see Author response image 1 below). To clarify this point we added the statement “which are not compromised by the fluorescence from the ChR2-EYFP transgene in the parenchyma (Madisen et al. 2012),” Line 628-629. Note that line-scan acquisitions without photoactivation stimulation did not trigger any progressive change in the vessel size or resting fluorescence.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Example of a pial arteriole filled with fluorescein dextran (cyan) in an Emx1-EYFP mouse (parenchyma labeled with YFP, in cyan).</title><p>The red line represents a line-scan to record the change in diameter. Due to the perivascular space surrounding the arterioles, the vessel walls are clearly identified and separated from the fluorescent parenchyma.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(4) Could the authors potentially extend the time course in panel e to show the recovery of the preparation to the baseline?</p></disp-quote><p>Because arterioles were only monitored for a 40-s period during a session of optogenetic stimulation/imaging we cannot extend panel e. Nonetheless, a 5 minutes interstimulus interval was observed to allow the full recovery of the preparation to the baseline. This now clarified line 640. Of note, the arteriole shown in panel d before indomethacin treatment fully recovered to baseline after this treatment.</p><disp-quote content-type="editor-comment"><p>Also, did the authors observe any 'abnormal' behavior of the vasculature after stimulation, such as large-amplitude oscillations? (5)</p></disp-quote><p>We did not specifically investigate resting state oscillations, such as vasomotion, but the 10-s long baseline recording for each measurement indicates no long lasting, abnormal and de novo behavior with a frequency higher than 0.1-0.2 Hz.</p><disp-quote content-type="editor-comment"><p>Can the authors show in vivo data from control experiments in EYFP-expressing or WT mice that underwent the same stimulation paradigm (Supplementary Figure 1 shows data from brain slices)?</p></disp-quote><p>The reviewer is correct to point out this important control, as optogenetic stimulation can induce a vascular response without channel rhodopsin activation at high power (see our study on the topic, Rungta et al, Nat Com 2017). We therefore tested this potential artefact in a WT mouse using our setup, with different intensities and durations of optogenetic stimulation.</p><p>Author response image 2A shows that stimulations of 10 seconds, 10 Hz, 1 mW, 5 ms pulses, i.e. the conditions we used for the experiments in Emx1 mice, did not induce dilation or constriction. Stimulation for 5 seconds with the same number of pulses, but with a higher power (4 mW), longer duration (20 ms pulses) and at a higher frequency elicited a small dilation in 1 of 2 pial arterioles (Author response image 2B). For this reason, we used only shorter (5ms) and less intense (1 mW) optogenetic stimulation to ensure that the observed dilation was solely due to Emx1 activation and not to light-induced artefactual dilation.</p><fig id="sa3fig2" position="float"><label>Author response image 2.</label><caption><title>Optogenetic stimulation in a wild-type mouse.</title><p>A. No diameter changes upon stimulations of 10 seconds, 10 Hz, 1 mW, 5 ms pulses, i.e. the conditions we used for the experiments in Emx1 mice. B. Stimulation of higher power (4 mW), longer duration (20 ms pulses) and at a higher frequency elicited a small dilation in 1 (grey traces) of 2 pial arterioles.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102424-sa3-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Figures 6 and 7: It is surprising that blockade of NPY Y1 receptors leads to a complete loss of the constriction response. As shown in Figure 7, the authors suggest that pyramidal neuron-released PGE2 (and glutamate) initiate several cascades acting on smooth muscle directly (PGE2-EP1/EP3), through astrocytes (Glu/COX-1/PGE2 or 20-HETE), or through NPY interneurons (Glu/NPY/Y1 or PGE2/NPY/Y1). This would imply that COX-1/2 and NPY/Y1 pathways act in series (as discussed by the authors). Besides the potential effects on NPY release mentioned in the discussion, could the authors comment if both (NPY and PGE2) pathways need to be co-activated in smooth muscle cells to cause constriction?</p></disp-quote><p>We thank the reviewer for raising this surprising complete loss of vasoconstriction by Y1 antagonism, despite the contribution of other vasoconstrictive pathways. We now discuss (lines 402-409) the possibility that activation of the neuronal Y1 receptors in pyramidal cells may also have contributed to the vasoconstriction by promoting glutamate and possibly PGE2 release. The combined activation of vascular and neuronal Y1 receptors may explain the complete blockage of optogenetically induced vasoconstriction by BIBP3226.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>The complete block of the constriction by BIBP3226 needs to be carefully considered.</p></disp-quote><p>We thank the reviewer for stressing this point also raised by Reviewer #1. As mentioned above we now discuss (lines 402-409) the possibility that activation of the neuronal Y1 receptors in pyramidal cells may also have contributed to the vasoconstriction by promoting glutamate and possibly PGE2 release. The combined activation of vascular and neuronal Y1 receptors may explain the complete blockage of optogenetically induced vasoconstriction by BIBP3226.</p></body></sub-article></article>